Skip to content
← All treatment topics

TREATMENT READING

Acute Myeloid Leukemia

Source sections for this topic, with the original link and date. Patient and professional reading are labelled separately.

Not medical advice · Not a complete treatment or trial directory

Made by Triangle.

Selected text from the National Cancer Institute, with the original link and date. Made by Triangle. This page is not an NCI PDQ summary. Source topics may be broader than an individual diagnosis.

72 sections
  1. Long-Term Effects of Cancer Treatment
  2. Therapy-Related Myeloid Neoplasms
  3. Treatment Option Overview for AML
  4. Phases of Therapy
  5. Supportive Care During Therapy
  6. Transfusion therapy
  7. Growth factors
  8. Antimicrobial therapy
  9. Treatment of Newly Diagnosed AML
  10. Treatment Options for Newly Diagnosed (Untreated; Remission Induction) AML
  11. Chemotherapy
  12. Selection of an anthracycline
  13. Addition of an FLT3 inhibitor
  14. Midostaurin
  15. Quizartinib
  16. Addition of gemtuzumab ozogamicin
  17. Liposomal daunorubicin-cytarabine (CPX-351)
  18. Older adults or adults with significant comorbid conditions
  19. Treatment of AML in Remission
  20. Chemotherapy
  21. Maintenance Therapy
  22. Midostaurin
  23. Oral azacitidine
  24. Hematopoietic Cell (Bone Marrow or Stem Cell) Transplant
  25. Allogeneic HCT
  26. Autologous hematopoietic stem cell transplant
  27. Treatment of Refractory or Recurrent AML
  28. Chemotherapy
  29. Intensive salvage chemotherapy
  30. Fludarabine, cytarabine, and filgrastim (FLAG)
  31. Mitoxantrone, etoposide, and cytarabine (MEC)
  32. Standard or high-dose cytarabine and mitoxantrone
  33. High-dose etoposide and cyclophosphamide
  34. Idarubicin and cytarabine
  35. Other intensive regimens
  36. Reduced-intensity therapy, including targeted therapy
  37. Gilteritinib
  38. Enasidenib
  39. Ivosidenib
  40. Revumenib
  41. Hypomethylating agents
  42. Gemtuzumab ozogamicin
  43. Clofarabine with or without cytarabine
  44. Allogeneic Hematopoietic Cell Transplant
  45. Treatment of Acute Promyelocytic Leukemia (APL)
  46. Treatment of Newly Diagnosed APL
  47. ATRA plus ATO for low- to intermediate-risk disease
  48. ATRA plus chemotherapy, followed by ATO-based consolidation therapy for high-risk disease
  49. Treatment of Recurrent APL
  50. ATO with or without chemotherapy
  51. HCT
  52. Smoking, previous chemotherapy treatment, and exposure to radiation may increase the risk of AML.
  53. Certain factors affect prognosis (chance of recovery) and treatment options.
  54. Treatment Option Overview
  55. Key Points
  56. There are different types of treatment for people with acute myeloid leukemia (AML).
  57. The treatment of AML usually has two phases.
  58. Patients receive supportive care for side effects of treatment.
  59. The following types of treatment are used:
  60. Chemotherapy
  61. Radiation therapy
  62. Chemotherapy with stem cell transplant
  63. Targeted therapy
  64. Other drug therapy
  65. New types of treatment are being tested in clinical trials.
  66. Treatment for acute myeloid leukemia may cause side effects.
  67. Follow-up care may be needed.
  68. Treatment of Untreated Acute Myeloid Leukemia
  69. Treatment of Acute Myeloid Leukemia in Remission
  70. Treatment of Refractory or Recurrent Acute Myeloid Leukemia
  71. Treatment of Acute Promyelocytic Leukemia
  72. Treatment of Recurrent Acute Promyelocytic Leukemia

Health professional · General Information About Acute Myeloid Leukemia (AML)

Long-Term Effects of Cancer Treatment

Source: Acute Myeloid Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: March 14, 2025. Captured 2026-09-09.

The risk of developing any long-term effects depends on the type and dose of treatment that was used and the age at which the patient underwent treatment.

A study of 30 patients who had AML that was in remission for at least 10 years demonstrated a 13% incidence of secondary malignancies.[8] Of 31 female long-term survivors of AML or acute lymphoblastic leukemia (ALL) diagnosed before age 40 years, 26 resumed normal menstruation after completion of therapy. Among 36 live offspring of survivors, two congenital problems occurred.[8]

Sources: 8 · 8

Most patients with AML who undergo intensive therapy are treated with an anthracycline. Anthracyclines have been associated with increased risk of congestive heart failure (CHF).[9] Anthracycline cardiotoxicity is dose-dependent. In one study, doxorubicin-related CHF was 5% at a lifetime cumulative dose of 400 mg/m2, rising to 26% at a cumulative dose of 550 mg/m2.[10] In many cases, heart failure can manifest as a late effect.[11] In an analysis of children who underwent treatment for acute leukemia, the cumulative incidence of CHF at 10 years was 1.7% in ALL and 7.5% in AML.[12]

Sources: 9 · 10 · 11 · 12

Patients who undergo allogeneic hematopoietic stem cell transplant can experience a large number of long-term or late side effects of treatment as a result of high-dose chemotherapy and/or radiation, and as an effect of chronic graft-versus-host disease and immunosuppression. These side effects may include chronic fatigue, thyroid and gonadal dysfunction, infertility, chronic infection, accelerated coronary heart disease, osteopenia, cataracts, iron overload, adverse psychological outcomes, and second cancers.[13-15]

Sources: 13 · 15

In the Bone Marrow Transplant Survivor Study, hematopoietic cell transplant survivors had accelerated aging and were 8.4 times more likely to be frail than their siblings (95% confidence interval [CI], 2.0−34.5; P = .003). In a multivariable analysis, frailty was associated with a 2.76-fold increase in the risk of death, compared with a nonfrail state (95% CI, 1.7−4.4; P < .001).[16]

Sources: 16

This page is made by Triangle. The reading above is selected source text, not a treatment recommendation, and it is not medical advice.

Health professional · Classification of AML

Therapy-Related Myeloid Neoplasms

Source: Acute Myeloid Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: March 14, 2025. Captured 2026-09-09.

Therapy-related myeloid neoplasms (t-MN) include AML (t-AML) and MDS (t-MDS) that arise secondary to cytotoxic chemotherapy and/or radiation therapy.[5] The therapy-related (or secondary) MDS are included because of their close clinicopathological relationships to therapy-related AML. Although these therapy-related disorders can be distinguished by the specific mutagenic agents involved, this distinction may be difficult to make because of the frequent overlapping use of multiple potentially mutagenic agents in treating cancer.[68] Because the associated cytogenetic abnormality, not the mutagenetic agent, determines prognosis and treatment it should be noted in the diagnosis.[10]

Sources: 5 · 68 · 10

Since t-MN have been associated with germline pathogenic variants in cancer susceptibility genes, considering germline genetic testing or genetic counseling is warranted in those with strong family histories of cancer.[69]

Sources: 69

Alkylating agent-related t-MN

The alkylating agent/radiation-related acute leukemias and myelodysplastic syndromes typically occur 5 to 6 years after exposure to the mutagenic agent, with a reported range of approximately 10 to 192 months.[70,71] The risk of occurrence is related to both the total cumulative dose of the alkylating agent and the age of the patient.

Sources: 70 · 71

Cytogenetic abnormalities have been observed in more than 90% of cases of t-MN and commonly include chromosomes 5 and/or 7.[70,72,73] Complex chromosomal abnormalities (≥3 distinct abnormalities) are the most common finding.[68,72-74]

Sources: 70 · 72 · 73 · 68 · 72 · 74

Topoisomerase II inhibitor-related t-MN

Topoisomerase II inhibitor-related t-MN occurs in patients treated with topoisomerase II inhibitors. The agents implicated are the epipodophyllotoxins etoposide and teniposide and the anthracyclines doxorubicin and 4-epi-doxorubicin.[70] The mean latency period from the time of institution of the causative therapy to the development of t-MN is approximately 2 years.[75]

Sources: 70 · 75

As with alkylating agent/radiation-related t-MN, the cytogenetic abnormalities are often complex.[68,72-74] The predominant cytogenetic finding involves chromosome 11q23 abnormalities and KMT2A pathogenic variants.[68,76]

Sources: 68 · 72 · 74 · 68 · 76

Health professional

Treatment Option Overview for AML

Source: Acute Myeloid Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: March 14, 2025. Captured 2026-09-09.

Health professional · Treatment Option Overview for AML

Phases of Therapy

Source: Acute Myeloid Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: March 14, 2025. Captured 2026-09-09.

The treatment of patients with acute myeloid leukemia (AML) is based on whether the disease is newly diagnosed (previously untreated), in remission, or recurrent. Also, the intensity of the treatment and the patient's overall health status are considered when choosing a treatment approach. Successful treatment of AML requires the control of bone marrow and systemic disease, and specific treatment of central nervous system (CNS) disease, if present. The cornerstone of this strategy includes systemically administered combination chemotherapy. Because only 5% or fewer of patients with AML develop CNS disease, prophylactic treatment is not indicated.[1,2]

Sources: 1 · 2

Newly diagnosed (untreated): Untreated AML is defined as newly diagnosed leukemia that has not been previously treated. The initial treatment for patients with newly diagnosed AML is often induction therapy that aims to induce a remission. In patients with AML, a complete remission (CR) is defined as a normal peripheral blood cell count (absolute neutrophil count >1,000/mm3 and platelet count >100,000/mm3) and normocellular marrow with less than 5% blasts in the marrow and no signs or symptoms of the disease. In addition, no signs or symptoms are evident of CNS leukemia or other extramedullary infiltration.[3] Modifications to the definition of CR have been proposed because some responses are deeper than a CR, and others may not meet all the criteria for a complete response. In addition, most AML patients meeting the criteria for CR have residual leukemia.[3]

Sources: 3 · 3

Table 2. Treatment Response Categories for Newly Diagnosed Acute Myeloid Leukemia
Response CategoryDefinition
ANC = absolute neutrophil count; CR = complete remission; CRh = CR with partial hematologic recovery; CRi = CR with incomplete hematologic recovery; CRMRD− = CR without measurable residual disease; MLFS = morphological leukemia-free state; PR = partial remission; RT–qPCR = reverse transcription–quantitative polymerase chain reaction.
CRMRD−If studied pretreatment, CR with negativity for a genetic marker by RT–qPCR, or CR with negativity by multicolor flow cytometry.
CRBone marrow blasts <5%; absence of circulating blasts and blasts with Auer rods; absence of extramedullary disease; ANC ≥1.0 × 109/L (1,000/microL); platelet count ≥100 × 109/L (100,000/microL).
CRhANC ≥0.5 x 109/L (500/microL) and platelet count ≥50 x 109/L (100,000/microL); otherwise all other CR criteria met.[4]
CRiAll CR criteria except for residual neutropenia (<1.0 × 109/L [1,000/microL]) or thrombocytopenia (<100 × 109/L [100,000/microL]).
MLFSBone marrow blasts <5%; absence of blasts with Auer rods; absence of extramedullary disease; no hematologic recovery required.
PRAll hematologic criteria of CR; decrease of bone marrow blast percentage to 5 to 25%; and decrease of pretreatment bone marrow blast percentage by at least 50%.
No responsePatients evaluable for response but not meeting criteria for CR, CRh, CRi, MLFS, or PR are categorized as having no response prior to the response landmark. Patients failing to achieve response by the designated landmark are designated as having refractory disease.

Sources: 4

In remission: When patients are in a remission after induction chemotherapy, consolidation chemotherapy is given, with the aim of deepening the response and consolidating the remission. Maintenance therapy is not included in most current treatment protocols and clinical trials. Consolidation therapy appears to be effective when given immediately after remission is achieved.[5]

Sources: 5

Persistent/recurrent disease: Despite intensive chemotherapy, some patients with newly diagnosed AML will not go into remission and have primary refractory disease. Also, some patients who are in a remission after induction and consolidation chemotherapy may have a return of their disease.[3] The rates of primary refractory disease and relapse vary with the age of the patient, genomic variants seen in the leukemia cells, and initial treatment given.

Sources: 3

Table 3. Treatment Response Categories for Persistent/Recurrent Acute Myeloid Leukemia
Response CategoryDefinition
CR = complete remission; CRh = CR with partial hematologic recovery; CRhMRD-LL = CR with partial hematologic recovery and measurable residual disease at a low level; CRi = CR with incomplete hematologic recovery; CRiMRD-LL = CR with incomplete hematologic recovery and measurable residual disease at a low level; CRMRD- = CR without measurable residual disease; CRMRD-LL = CR with measurable residual disease detection at a low level; MRD = measurable residual disease; MRD- = absence of measurable residual disease; MRD+ = presence of measurable residual disease; MLFS = morphological leukemia-free state; PR = partial response; RT–qPCR = reverse transcription–quantitative polymerase chain reaction.
Primary refractory diseaseNo CR, CRh, or CRi at the response landmark (i.e., after two courses of intensive induction treatment) or a defined landmark (e.g., 180 days after commencing less-intensive therapy).
Relapsed disease (after CR, CRh, or CRi)Bone marrow blasts ≥5%; or reappearance of blasts in the blood in at least two peripheral blood samples obtained at least 1 week apart; or development of extramedullary disease.
MRD relapse (after CR, CRh, or CRi without MRD-)Defined by one of the following:
Conversion from MRD- to MRD+, independent of method; or
Increase of MRD copy numbers ≥1 log10 between any two positive samples in patients with CRMRD-LL, CRhMRD-LL, or CRiMRD-LL by qPCR.
Either result should be rapidly confirmed in a second consecutive sample from the same tissue source.
Stable diseaseAbsence of CRMRD-, CR, CRi, PR, MLFS; and criteria for progressive disease not met.
Progressive diseaseEvidence for an increase in bone marrow blast percentage and/or increase of absolute blast counts in the blood:
>50% increase in marrow blasts; or
>50% increase in peripheral blasts in the absence of differentiation syndrome; or
New extramedullary disease.

Health professional · Treatment Option Overview for AML

Supportive Care During Therapy

Source: Acute Myeloid Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: March 14, 2025. Captured 2026-09-09.

Because myelosuppression is an anticipated consequence of both the leukemia and its treatment with chemotherapy, patients must be closely monitored during therapy. Facilities must be available for hematologic support with multiple blood fractions, including platelet transfusions, and for the treatment of related infectious complications.[6]

Sources: 6

Health professional · Treatment Option Overview for AML / Supportive Care During Therapy

Transfusion therapy

Source: Acute Myeloid Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: March 14, 2025. Captured 2026-09-09.

Supportive care during remission induction treatment should routinely include red blood cell and platelet transfusions, when appropriate.[7,8] Rapid marrow ablation with consequent earlier marrow regeneration decreases morbidity and mortality. Randomized trials have shown similar outcomes for patients who received prophylactic platelet transfusions at a level of 10,000/mm3 rather than 20,000/mm3.[9] The incidence of platelet alloimmunization was similar among groups randomly assigned to receive pooled platelet concentrates from random donors; filtered, pooled platelet concentrates from random donors; ultraviolet B-irradiated, pooled platelet concentrates from random donors; or filtered platelets obtained by apheresis from single random donors.[10]

Sources: 7 · 8 · 9 · 10

No good evidence exists to support granulocyte transfusions in the treatment of AML. A multicenter randomized trial (RING [NCT00627393]) was conducted to address the utility of granulocyte transfusions in the setting of infections.[11] There was no difference between the granulocyte and control arms for the composite primary end point of survival plus microbial response at 42 days after randomization. However, the power to detect a true beneficial effect was low because enrollment was half that of the planned study size.

Sources: RING · 11

Health professional · Treatment Option Overview for AML / Supportive Care During Therapy

Growth factors

Source: Acute Myeloid Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: March 14, 2025. Captured 2026-09-09.

The following growth factors have been studied in the treatment of AML:

Colony-stimulating factors: Granulocyte colony–stimulating factor and granulocyte-macrophage colony–stimulating factor have been studied in an effort to shorten the period of granulocytopenia associated with leukemia treatment.[12] If used, these agents are administered after administration of chemotherapy. Although the use of growth factors decreases the time to neutrophil recovery by 2 to 5 days, and decreases rates of febrile neutropenia and duration of hospitalization, randomized clinical trials have not shown an impact of growth factors on overall survival and their cost-effectiveness has been inconsistently reported.[13,14] Use of growth factors is not routinely recommended in the remission induction setting.

Sources: 12 · 13 · 14

Erythropoiesis-stimulating agents: Anemia associated with the diagnosis of AML and induction chemotherapy is managed primarily with red blood transfusions. Unlike myelodysplastic syndromes, there is no role for the use of erythropoiesis stimulating agents (e.g., epoetin alfa and darbepoetin) during the treatment of AML.

Thrombopoietin mimetics: Clinical trials have assessed the use of thrombopoietin mimetics in the treatment of AML. Eltrombopag as a single agent was tested in a multicenter, randomized, placebo-controlled, double-blind, phase I/II trial of 98 patients with platelet counts less than 30 × 109/L as a result of AML or MDS. No significant improvements in platelet counts were recorded. Significant hemorrhage was reported in ten (16%) patients given eltrombopag and nine (26%) patients given placebo. No difference in disease progression or overall survival was observed.[15]Eltrombopag appeared to hasten platelet recovery and reduce the number of platelet transfusions needed when added in an unblinded fashion to induction chemotherapy in older FLT3-negative AML patients.[16] However, in a separate, randomized double-blind study of 148 patients, eltrombopag or placebo was added to high-dose induction chemotherapy.[17] The results of this study did not indicate any clinical benefit of eltrombopag over placebo. Given the minimal efficacy signal at this point, eltrombopag is not routinely recommended in the supportive care or remission induction setting.

Sources: 15 · 16 · 17

Health professional · Treatment Option Overview for AML / Supportive Care During Therapy

Antimicrobial therapy

Source: Acute Myeloid Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: March 14, 2025. Captured 2026-09-09.

Empiric broad spectrum antimicrobial therapy is an absolute necessity for febrile patients who are profoundly neutropenic.[18,19] Careful instruction in personal hand hygiene, dental care, and recognition of early signs of infection are appropriate in all patients. Elaborate isolation facilities (including filtered air, sterile food, and gut flora sterilization) are not indicated.[20,21] Likewise, there are no advantages to eating a cooked neutropenic diet, as demonstrated in randomized trials.[22]

Sources: 18 · 19 · 20 · 21 · 22

Antibiotic prophylaxis with a fluoroquinolone and antifungal prophylaxis with an oral triazole or parenteral echinocandin is appropriate for patients with expected prolonged, profound neutropenia (<100/mm3 for 2 weeks for profound neutropenia lasting >7 days).[23] Unlike patients undergoing treatment for acute lymphoblastic lymphoma, Pneumocystis jirovecii prophylaxis is not routinely employed.

Sources: 23

Nucleoside analog-based antiviral prophylaxis, such as acyclovir, is appropriate for patients who are seropositive for herpes simplex virus undergoing induction chemotherapy.[23]

Sources: 23

Health professional

Treatment of Newly Diagnosed AML

Source: Acute Myeloid Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: March 14, 2025. Captured 2026-09-09.

Health professional · Treatment of Newly Diagnosed AML

Treatment Options for Newly Diagnosed (Untreated; Remission Induction) AML

Source: Acute Myeloid Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: March 14, 2025. Captured 2026-09-09.

Treatment options for newly diagnosed (untreated; remission induction) acute myeloid leukemia (AML) include:

Chemotherapy.

Sources: Chemotherapy

Health professional · Treatment of Newly Diagnosed AML / Treatment Options for Newly Diagnosed (Untreated; Remission Induction) AML

Chemotherapy

Source: Acute Myeloid Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: March 14, 2025. Captured 2026-09-09.

Chemotherapy for AML is divided into the following two general categories:

Intensive remission-induction chemotherapy.

Nonintensive chemotherapy.

One of the following combination chemotherapy regimens may be used as intensive remission induction therapy:

Cytarabine plus daunorubicin.[1,2]

Sources: 1 · 2

Cytarabine plus idarubicin.[3-6]

Sources: 3 · 6

Cytarabine plus mitoxantrone.[7]

Sources: 7

Cytarabine plus anthracycline plus midostaurin.[8]

Sources: 8

Cytarabine plus anthracycline plus gemtuzumab ozogamicin.[9]

Sources: 9

Liposomal daunorubicin-cytarabine (CPX-351).[10]

Sources: 10

Intrathecal cytarabine or methotrexate may be used to treat central nervous system (CNS) leukemia, if present.

The two-drug regimen of cytarabine given as a continuous infusion for 7 days and a 3-day course of anthracycline (the so-called 7 + 3 induction therapy) results in a complete response rate of approximately 65%. In most instances, there is no further clinical benefit when adding potentially non-cross−resistant drugs (such as fludarabine, topoisomerase inhibitors, thioguanine, mitoxantrone, histone deacetylases inhibitors, or clofarabine) to a 7 + 3 regimen. Cladribine, when added to 7 + 3 induction chemotherapy, showed improved remission rates [11] and survival rates [12] across two randomized controlled trials, but this regimen has not been widely adopted in the absence of confirmatory trials. The addition of midostaurin and gemtuzumab ozogamicin to intensive induction chemotherapy is discussed below.

Sources: 11 · 12

The choice of anthracycline and the dose-intensity of anthracycline may influence the survival of patients with AML. Idarubicin appeared to be more effective than daunorubicin, particularly in younger adults, although the doses of idarubicin and daunorubicin may not have been equivalent.[3-6] No significant survival difference between daunorubicin and mitoxantrone has been reported.[13]

Sources: 3 · 6 · 13

Health professional · Treatment of Newly Diagnosed AML / Treatment Options for Newly Diagnosed (Untreated; Remission Induction) AML / Chemotherapy

Selection of an anthracycline

Source: Acute Myeloid Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: March 14, 2025. Captured 2026-09-09.

At present, there is no conclusive evidence to recommend one anthracycline over another.

Evidence (anthracyclines):

In a systematic review and meta-analysis, 18 randomized controlled trials that included 6,755 patients assessed the use of idarubicin versus daunorubicin as part of induction chemotherapy.[14]

Sources: 14

In a systematic review and meta-analysis, 18 randomized controlled trials that included 6,755 patients assessed the use of idarubicin versus daunorubicin as part of induction chemotherapy.[14]

The use of idarubicin led to improved outcomes, including overall survival (OS), when compared with daunorubicin (12 studies, 5,976 patients; hazard ratio [HR], 0.90; 95% confidence interval [CI], 0.84−0.96; P = .0008). However, there was an increased risk of death during induction (14 studies, 6,349 patients; relative risk [RR], 1.18; 95% CI, 1.01−1.36; P = .03) and mucositis (five studies, 2,000 patients; RR, 1.22; 95% CI, 1.04−1.44; P = .02) with idarubicin as compared with daunorubicin. Moreover, the survival benefit for idarubicin was no longer present if a daunorubicin dose of at least 180 mg/m2 was used (four studies, 2,867 patients; HR, 0.91; 95% CI, 0.82−1.00; P = .06).

In patients aged 60 years and younger, outcomes for those who received daunorubicin (90 mg/m2/dose, total induction dosing at 270 mg/m2) were superior to those who received more traditional dosing (45 mg/m2/dose; total dose = 135 mg/m2). The complete remission (CR) rate was 71% versus 57% (P < .001), and the median survival was 24 months versus 16 months (P = .003).[15]

Sources: 15

No randomized comparison data between daunorubicin at 270 mg/m2 and daunorubicin at 180 mg/m2, or between daunorubicin at 270 mg/m2 and idarubicin, are available.

Health professional · Treatment of Newly Diagnosed AML / Treatment Options for Newly Diagnosed (Untreated; Remission Induction) AML / Chemotherapy

Addition of an FLT3 inhibitor

Source: Acute Myeloid Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: March 14, 2025. Captured 2026-09-09.

Variants in the tyrosine kinase domain (TKD) and internal tandem duplications (ITD) of the FLT3 gene are frequent in AML and are often associated with an inferior outcome.

Health professional · Treatment of Newly Diagnosed AML / Treatment Options for Newly Diagnosed (Untreated; Remission Induction) AML / Chemotherapy / Addition of an FLT3 inhibitor

Midostaurin

Source: Acute Myeloid Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: March 14, 2025. Captured 2026-09-09.

Evidence (midostaurin):

A multicenter, randomized, phase III trial (NCT00651261) included patients with FLT3-altered AML. Patients received either the FLT3/multikinase inhibitor, midostaurin, or placebo in addition to cytarabine and daunorubicin induction chemotherapy. The addition of midostaurin led to improved survival (median, 75 vs. 26 months; HR for death, 0.78; one-sided P = .009).[8]

Sources: NCT00651261 · 8

A multicenter, randomized, phase III trial (NCT00651261) included patients with FLT3-altered AML. Patients received either the FLT3/multikinase inhibitor, midostaurin, or placebo in addition to cytarabine and daunorubicin induction chemotherapy. The addition of midostaurin led to improved survival (median, 75 vs. 26 months; HR for death, 0.78; one-sided P = .009).[8]

The event-free survival (defined as the time from randomization to relapse, death from any cause, or failure to achieve protocol-specified CR) was improved for patients in the midostaurin arm (HR for event or death, 0.78; one-sided P = .002), and the survival benefit was consistent across all FLT3 variant subtypes. The rates of CR (59% vs. 54%) and time to neutrophil count recovery were similar between the two arms.[8][Level of evidence A1]

Sources: 8 · Level of evidence A1

The U.S. Food and Drug Administration (FDA) approved midostaurin in combination with induction therapy for patients with AML and any FLT3 variant.

Health professional · Treatment of Newly Diagnosed AML / Treatment Options for Newly Diagnosed (Untreated; Remission Induction) AML / Chemotherapy / Addition of an FLT3 inhibitor

Quizartinib

Source: Acute Myeloid Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: March 14, 2025. Captured 2026-09-09.

Evidence (quizartinib):

A multicenter, randomized, phase III trial (NCT02668653) included patients with FLT3-ITD–altered AML. Patients received either the selective ITD-specific FLT3 inhibitor, quizartinib, or placebo in addition to cytarabine and daunorubicin induction chemotherapy. The addition of quizartinib led to improved survival (median, 31.9 vs. 15.1 months; HR for death, 0.78; P = .032).[16]

Sources: NCT02668653 · 16

A multicenter, randomized, phase III trial (NCT02668653) included patients with FLT3-ITD–altered AML. Patients received either the selective ITD-specific FLT3 inhibitor, quizartinib, or placebo in addition to cytarabine and daunorubicin induction chemotherapy. The addition of quizartinib led to improved survival (median, 31.9 vs. 15.1 months; HR for death, 0.78; P = .032).[16]

The EFS (defined as the time from randomization to lack of CR within 42 days from the start of the last induction cycle, relapse, or death from any cause, whichever occurred first) was similar for patients in the quizartinib and placebo arms (HR for event or death, 0.92; 95% CI, 0.75–1.11; P = .24). The rates of CR and time to neutrophil count recovery were similar between the two arms.[16][Level of evidence A1]

Sources: 16 · Level of evidence A1

The FDA approved quizartinib in combination with induction therapy for patients with AML and an FLT3-ITD variant but not for patients with other FLT3 variants, such as FLT3-TKD.

The addition of an FLT3 inhibitor to induction chemotherapy is the standard of care for patients with FLT3-altered AML who are eligible for intensive chemotherapy. An ongoing study (NCT03836209) is evaluating which FLT3 inhibitor is best for patients with FLT3-ITD AML receiving up-front chemotherapy. Additional studies are evaluating FLT3 inhibitors in combination with hypomethylating agents and venetoclax in patients who are not candidates for intensive therapy.

Sources: NCT03836209

Health professional · Treatment of Newly Diagnosed AML / Treatment Options for Newly Diagnosed (Untreated; Remission Induction) AML / Chemotherapy

Addition of gemtuzumab ozogamicin

Source: Acute Myeloid Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: March 14, 2025. Captured 2026-09-09.

Evidence (gemtuzumab ozogamicin):

In a meta-analysis of more than 3,000 patients, the addition of the CD33-directed immunotoxin gemtuzumab ozogamicin to cytarabine plus anthracycline or clofarabine plus anthracycline led to a small increase in the OS rate at 5 years (30.7% vs. 34.6%; HR, 0.90; 95% CI, 0.82−0.98; P = .01).[9] The FDA label for gemtuzumab ozogamicin includes a boxed warning about the risk of hepatotoxicity, including severe or fatal hepatic sinusoidal obstruction syndrome.

Sources: 9

In a meta-analysis of more than 3,000 patients, the addition of the CD33-directed immunotoxin gemtuzumab ozogamicin to cytarabine plus anthracycline or clofarabine plus anthracycline led to a small increase in the OS rate at 5 years (30.7% vs. 34.6%; HR, 0.90; 95% CI, 0.82−0.98; P = .01).[9] The FDA label for gemtuzumab ozogamicin includes a boxed warning about the risk of hepatotoxicity, including severe or fatal hepatic sinusoidal obstruction syndrome.

The improvement in the 5-year OS rate was seen across all ages, but this effect was greatest in patients with favorable-risk cytogenetics (55.2% vs. 76.3%; HR, 0.47; 95% CI, 0.31−0.73; P = .0005), and to a lesser extent with intermediate-risk cytogenetics (34.1% vs. 39.4%; HR, 0.84; 95% CI, 0.75−0.95; P = .007). It was not seen in patients with an adverse-risk karyotype.[9][Level of evidence A1]

Sources: 9 · Level of evidence A1

In contrast, gemtuzumab ozogamicin did not improve the 1-year survival rate of older patients who received low-dose cytarabine, although the CR rate increased from 17% to 30% (odds ratio [OR], 0.48; 95% CI, 0.32–0.73; P = .006).[17]

Sources: 17

Health professional · Treatment of Newly Diagnosed AML / Treatment Options for Newly Diagnosed (Untreated; Remission Induction) AML / Chemotherapy

Liposomal daunorubicin-cytarabine (CPX-351)

Source: Acute Myeloid Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: March 14, 2025. Captured 2026-09-09.

CPX-351 is a two-drug liposomal encapsulation that delivers cytarabine and daunorubicin at a fixed 5:1 synergistic molar ratio.

Evidence (CPX-351):

A multicenter trial investigated CPX-351 in patients aged 60 to 75 years with therapy-related AML, AML with a history of myelodysplastic syndrome (MDS), or AML with myelodysplasia-related changes.[10]

Sources: 10

A multicenter trial investigated CPX-351 in patients aged 60 to 75 years with therapy-related AML, AML with a history of myelodysplastic syndrome (MDS), or AML with myelodysplasia-related changes.[10]

Compared with 7 + 3 induction chemotherapy, CPX-351 resulted in a better overall remission rate (47.7% vs. 33.3%; P = .016), and improved median OS (9.56 vs. 5.95 months; HR, 0.69; 95% CI, 0.52−0.90; P = .003).[10][Level of evidence A1]

Sources: 10 · Level of evidence A1

The rates of early mortality and toxicities were similar between the two arms. However, the median time to recovery of neutrophils and platelets was longer for CPX-351 (35.0 and 36.5 days, respectively) as compared with 7 + 3 induction chemotherapy (29 and 29 days, respectively).

Health professional · Treatment of Newly Diagnosed AML / Treatment Options for Newly Diagnosed (Untreated; Remission Induction) AML / Chemotherapy

Older adults or adults with significant comorbid conditions

Source: Acute Myeloid Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: March 14, 2025. Captured 2026-09-09.

Some patients may decline or be too frail for intensive induction chemotherapy. Low-dose cytarabine, decitabine, azacitidine, or best supportive care can be considered equivalently effective treatment approaches for older patients with AML who decline traditional 7 + 3 induction chemotherapy. Unlike a succinct course of 7 + 3 induction, these less-intensive therapies are continued indefinitely, as long as the patient is deriving benefit (i.e., until disease progression or significant toxicity occurs).

One of the following chemotherapy regimens may be used as less-intensive therapy:

Hypomethylating agents (azacitidine and decitabine).

Low-dose cytarabine.

Venetoclax plus hypomethylating agents or low-dose cytarabine.

Glasdegib plus low-dose cytarabine.

Ivosidenib with or without azacitidine.

Enasidenib.

Intrathecal cytarabine or methotrexate may be used to treat CNS leukemia, if present.

Evidence (chemotherapy for patients who decline intensive remission induction therapy):

Hypomethylating agents: The hypomethylating agents azacitidine and decitabine are used commonly in this population of older patients, particularly in the United States. Although approval of the drugs by the FDA is for an MDS indication, the registration studies leading to approval included patients with 20% to 30% myeloblasts, or what would now be considered oligoblastic AML.[18,19]

Sources: 18 · 19

Hypomethylating agents: The hypomethylating agents azacitidine and decitabine are used commonly in this population of older patients, particularly in the United States. Although approval of the drugs by the FDA is for an MDS indication, the registration studies leading to approval included patients with 20% to 30% myeloblasts, or what would now be considered oligoblastic AML.[18,19]

Azacitidine: An international phase III trial (NCT01074047) randomly assigned patients with AML who were 65 years or older to receive either azacitidine or conventional regimens (7 + 3 induction, low-dose cytarabine, or best supportive care alone).[20]

Sources: NCT01074047 · 20

Hypomethylating agents: The hypomethylating agents azacitidine and decitabine are used commonly in this population of older patients, particularly in the United States. Although approval of the drugs by the FDA is for an MDS indication, the registration studies leading to approval included patients with 20% to 30% myeloblasts, or what would now be considered oligoblastic AML.[18,19] › Azacitidine: An international phase III trial (NCT01074047) randomly assigned patients with AML who were 65 years or older to receive either azacitidine or conventional regimens (7 + 3 induction, low-dose cytarabine, or best supportive care alone).[20]

Azacitidine led to a median OS of 10.4 months (95% CI, 8.0−12.7) as compared with 6.5 months (95% CI, 5.0−8.6) with conventional regimens (HR, 0.85; 95% CI, 0.69−1.03; P = .1009).[20][Level of evidence A1]

Sources: 20 · Level of evidence A1

Hypomethylating agents: The hypomethylating agents azacitidine and decitabine are used commonly in this population of older patients, particularly in the United States. Although approval of the drugs by the FDA is for an MDS indication, the registration studies leading to approval included patients with 20% to 30% myeloblasts, or what would now be considered oligoblastic AML.[18,19]

Decitabine: One phase III trial randomly assigned 485 patients with AML who were older than 65 years to receive either decitabine (n = 242) or their preferred choice (n = 243) of either supportive care (n = 28) or low-dose cytarabine (n = 215).[21]Compared with treatment for 5 consecutive days, treatment for 10 consecutive days may lead to higher response rates, particularly in those with TP53 variants and/or unfavorable cytogenetic features.[22][Level of evidence C3]

Sources: 21 · 22 · Level of evidence C3

Hypomethylating agents: The hypomethylating agents azacitidine and decitabine are used commonly in this population of older patients, particularly in the United States. Although approval of the drugs by the FDA is for an MDS indication, the registration studies leading to approval included patients with 20% to 30% myeloblasts, or what would now be considered oligoblastic AML.[18,19] › Decitabine: One phase III trial randomly assigned 485 patients with AML who were older than 65 years to receive either decitabine (n = 242) or their preferred choice (n = 243) of either supportive care (n = 28) or low-dose cytarabine (n = 215).[21]Compared with treatment for 5 consecutive days, treatment for 10 consecutive days may lead to higher response rates, particularly in those with TP53 variants and/or unfavorable cytogenetic features.[22][Level of evidence C3]

Although rates of CR + CRp (CR with incomplete platelet recovery) were more than double in the decitabine arm (17.8%) compared with the treatment-choice arm (7.8%) (P = .001), median OS was not significantly improved for patients receiving decitabine (7.7 months) compared with the treatment of choice (5.0 months) (HR for death for decitabine, 0.85; 95% CI, .69–1.04; P = .11).

Low-dose cytarabine: Older adults who decline intensive remission-induction therapy or are considered ineligible for intensive remission-induction therapy may derive benefit from low-dose cytarabine, administered twice daily for 10 days in cycles repeated every 4 to 6 weeks.[23]

Sources: 23

Low-dose cytarabine: Older adults who decline intensive remission-induction therapy or are considered ineligible for intensive remission-induction therapy may derive benefit from low-dose cytarabine, administered twice daily for 10 days in cycles repeated every 4 to 6 weeks.[23]

The CR rate using this regimen was 18% compared with 1% for patients treated with hydroxyurea (P = .006).

Survival with low-dose cytarabine was better than was survival with hydroxyurea (OR, 0.60; 95% CI, 0.44–0.81; P = .009).[23][Level of evidence A1]

Sources: 23 · Level of evidence A1

Venetoclax plus hypomethylating agents or low-dose cytarabine: The FDA approved venetoclax, an inhibitor of the anti-apoptotic protein BCL2, in combination with low-dose cytarabine or a hypomethylating agent for the treatment of AML in patients aged 75 years or older, and those who cannot undergo 7 + 3 induction chemotherapy because of comorbidities. Approval was granted based on the results of two studies.

Venetoclax plus hypomethylating agents or low-dose cytarabine: The FDA approved venetoclax, an inhibitor of the anti-apoptotic protein BCL2, in combination with low-dose cytarabine or a hypomethylating agent for the treatment of AML in patients aged 75 years or older, and those who cannot undergo 7 + 3 induction chemotherapy because of comorbidities. Approval was granted based on the results of two studies.

The first study (NCT02203773) was a nonrandomized, open-label, phase Ib clinical trial of venetoclax in combination with azacitidine or decitabine.[24]

Sources: NCT02203773 · 24

Venetoclax plus hypomethylating agents or low-dose cytarabine: The FDA approved venetoclax, an inhibitor of the anti-apoptotic protein BCL2, in combination with low-dose cytarabine or a hypomethylating agent for the treatment of AML in patients aged 75 years or older, and those who cannot undergo 7 + 3 induction chemotherapy because of comorbidities. Approval was granted based on the results of two studies. › The first study (NCT02203773) was a nonrandomized, open-label, phase Ib clinical trial of venetoclax in combination with azacitidine or decitabine.[24]

In this study, 35 (61%; 95% CI, 47.6%−74.0%) of 57 patients had CR or CR with incomplete hematologic recovery (CRi). The median duration of response for all patients with a response (CR + CRi + partial remission [PR]) was 8.4 months (range, 4.7−11.7; n = 36).

Venetoclax plus hypomethylating agents or low-dose cytarabine: The FDA approved venetoclax, an inhibitor of the anti-apoptotic protein BCL2, in combination with low-dose cytarabine or a hypomethylating agent for the treatment of AML in patients aged 75 years or older, and those who cannot undergo 7 + 3 induction chemotherapy because of comorbidities. Approval was granted based on the results of two studies.

The second study (NCT02287233) was a phase I/IIb study of venetoclax in combination with low-dose cytarabine in 82 patients with newly diagnosed AML, including patients with previous exposure to a hypomethylating agent for an antecedent hematologic disorder such as MDS.[25]

Sources: NCT02287233 · 25

Venetoclax plus hypomethylating agents or low-dose cytarabine: The FDA approved venetoclax, an inhibitor of the anti-apoptotic protein BCL2, in combination with low-dose cytarabine or a hypomethylating agent for the treatment of AML in patients aged 75 years or older, and those who cannot undergo 7 + 3 induction chemotherapy because of comorbidities. Approval was granted based on the results of two studies. › The second study (NCT02287233) was a phase I/IIb study of venetoclax in combination with low-dose cytarabine in 82 patients with newly diagnosed AML, including patients with previous exposure to a hypomethylating agent for an antecedent hematologic disorder such as MDS.[25]

In the 82 patients enrolled in the study, the CR/CRi rate was 54% (95% CI, 42%−65%), with a median duration of remission of 8.1 months (95% CI, 5.3−14.9 months). The median OS for all patients, irrespective of response, was 10.1 months (95% CI, 5.7−14.2 months).

The most common adverse events with venetoclax combinations are gastrointestinal symptoms and myelosuppression, which may require delays between cycles, growth factor support, or decreased duration of venetoclax administration per cycle. Additionally, appropriate prophylactic measures are typically taken to prevent tumor lysis syndrome.[25][Level of evidence C3]

Sources: 25 · Level of evidence C3

Glasdegib plus low-dose cytarabine: Glasdegib, an oral inhibitor of the hedgehog pathway, combined with low-dose cytarabine was compared with low-dose cytarabine alone in a randomized, phase II open-label study that included 116 patients with AML who were aged 75 years or older or who had severe comorbid conditions (cardiac disease, renal impairment, or Eastern Cooperative Oncology Group performance status 2).[26] Similar to venetoclax, the FDA approved glasdegib in combination with low-dose cytarabine for the treatment of AML in patients aged 75 years or older or who are unable to receive intensive induction chemotherapy.

Sources: 26

Glasdegib plus low-dose cytarabine: Glasdegib, an oral inhibitor of the hedgehog pathway, combined with low-dose cytarabine was compared with low-dose cytarabine alone in a randomized, phase II open-label study that included 116 patients with AML who were aged 75 years or older or who had severe comorbid conditions (cardiac disease, renal impairment, or Eastern Cooperative Oncology Group performance status 2).[26] Similar to venetoclax, the FDA approved glasdegib in combination with low-dose cytarabine for the treatment of AML in patients aged 75 years or older or who are unable to receive intensive induction chemotherapy.

Of the 78 patients with AML who received glasdegib plus low-dose cytarabine, 24% (n = 19) of patients had a CR or CRi compared with 5% (2 of 38) of patients who received low-dose cytarabine alone. The median OS was 8.3 months (80%; CI, 6.6–9.5) for patients who received glasdegib/low-dose cytarabine and 4.3 months (80%; CI, 2.9–4.9) for patients who received low-dose cytarabine alone in patients with AML (HR, 0.46; 80% CI, 0.35–0.62; P = .0002).[26][Level of evidence A1]

Sources: 26 · Level of evidence A1

Ivosidenib: For older or frail patients with AML and IDH1 variants, the IDH1 inhibitor ivosidenib is an option. The FDA approved ivosidenib alone or in combination with azacitidine for the treatment of AML that has a susceptible IDH1 variant (detected by an FDA-approved diagnostic test) in adults aged 75 years or older with newly diagnosed AML or who have comorbidities that preclude the use of intensive induction chemotherapy. Within the context of a phase I study, 34 patients with newly diagnosed IDH1-altered AML who were not candidates for intensive induction chemotherapy were treated with single-agent ivosidenib.[27]The combination of azacitidine and ivosidenib was evaluated in a double-blind, randomized, placebo-controlled, phase III trial in patients with newly diagnosed AML who were not eligible for intensive induction chemotherapy. The intention-to-treat analysis included 72 patients treated with azacitidine and ivosidenib and 74 patients treated with azacitidine and placebo. A supplemental new drug application for ivosidenib in combination with azacitidine for patients with untreated IDH1-altered AML is under priority review with the FDA.[28]

Sources: 27 · 28

Ivosidenib: For older or frail patients with AML and IDH1 variants, the IDH1 inhibitor ivosidenib is an option. The FDA approved ivosidenib alone or in combination with azacitidine for the treatment of AML that has a susceptible IDH1 variant (detected by an FDA-approved diagnostic test) in adults aged 75 years or older with newly diagnosed AML or who have comorbidities that preclude the use of intensive induction chemotherapy. Within the context of a phase I study, 34 patients with newly diagnosed IDH1-altered AML who were not candidates for intensive induction chemotherapy were treated with single-agent ivosidenib.[27]The combination of azacitidine and ivosidenib was evaluated in a double-blind, randomized, placebo-controlled, phase III trial in patients with newly diagnosed AML who were not eligible for intensive induction chemotherapy. The intention-to-treat analysis included 72 patients treated with azacitidine and ivosidenib and 74 patients treated with azacitidine and placebo. A supplemental new drug application for ivosidenib in combination with azacitidine for patients with untreated IDH1-altered AML is under priority review with the FDA.[28]

Differentiation syndrome was reported in 6 patients (18%), but did not require treatment discontinuation.

The rate of CR plus CRi was 42.4% (95% CI, 25.5%−60.8%), with a median duration of response that was not reached (lower bound of the 95% CI was 4.6 months).

For all 34 patients on the study, the median OS was 12.6 months (95% CI, 4.5−25.7).[27][Level of evidence C3]

Sources: 27 · Level of evidence C3

At a median follow-up of 12.4 months, the primary end point of EFS was improved in patients who received azacitidine and ivosidenib, compared with patients who received azacitidine and placebo (HR, 0.33; 95% CI, 0.16–0.69).

The median OS was 24 months for patients who received azacitidine and ivosidenib and 7.9 months for patients who received azacitidine and placebo (HR for death, 0.44; 95% CI, 0.27–0.73).

Differentiation syndrome occurred in 14% of patients who received azacitidine and ivosidenib and 8% of patients who received azacitidine and placebo. The incidence of bleeding events was 41% with azacitidine and ivosidenib and 29% with azacitidine and placebo. Infection of any grade was seen in 28% of patients who received azacitidine and ivosidenib and 49% of patients who received azacitidine and placebo. For more information about differentiation syndrome, see the Treatment of Newly Diagnosed Acute Promyelocytic Leukemia section.[28][Level of evidence A1]

Sources: Treatment of Newly Diagnosed Acute Promyelocytic Leukemia · 28 · Level of evidence A1

Enasidenib: For patients with AML and IDH2 variants, the IDH2 inhibitor enasidenib is an option for older or frail patients. Although it does not have approval in this setting, enasidenib monotherapy was evaluated in a phase I/II trial in patients with newly diagnosed AML who were not eligible for standard chemotherapy.[29]

Sources: 29

Enasidenib: For patients with AML and IDH2 variants, the IDH2 inhibitor enasidenib is an option for older or frail patients. Although it does not have approval in this setting, enasidenib monotherapy was evaluated in a phase I/II trial in patients with newly diagnosed AML who were not eligible for standard chemotherapy.[29]

Of the 39 patients enrolled, seven (18%) had CR, one (3%) had CRi, and two (5%) had a PR.

Median OS for all patients was 11.3 months (95% CI, 5.7−15.1), and was not reached for patients who had a response.[29][Level of evidence C3]

Sources: 29 · Level of evidence C3

Health professional

Treatment of AML in Remission

Source: Acute Myeloid Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: March 14, 2025. Captured 2026-09-09.

Although individual patients with acute myeloid leukemia (AML) have been reported to have long disease-free survival (DFS) or cure with a single cycle of chemotherapy,[1] consolidation therapy is always indicated in therapy that is planned with curative intent. In a small randomized study conducted by the Eastern Cooperative Oncology Group, all patients who did not receive consolidation therapy experienced a relapse after a short median complete remission (CR) duration.[2]

Sources: 1 · 2

Treatment options for AML in remission (consolidation phase) include:

Chemotherapy with short-term (3−4 cycles), relatively intensive chemotherapy with cytarabine-based regimens similar to standard induction clinical trials (consolidation chemotherapy) and consolidation chemotherapy with more dose-intensive cytarabine-based treatment.

Sources: Chemotherapy

Maintenance therapy (longer-term therapy at lower doses) has not been shown to benefit AML patients in a number of studies, but two strategies have shown a benefit:

Sources: Maintenance therapy

Maintenance therapy (longer-term therapy at lower doses) has not been shown to benefit AML patients in a number of studies, but two strategies have shown a benefit:

Midostaurin in patients with FLT3-altered AML.

Sources: Midostaurin

Oral azacitidine.

Sources: Oral azacitidine

Hematopoietic cell (bone marrow or stem cell) transplant.

Sources: Hematopoietic cell (bone marrow or stem cell) transplant

Hematopoietic cell (bone marrow or stem cell) transplant.

High-dose chemotherapy with autologous peripheral blood stem cell rescue.

High-dose marrow-ablative or reduced-intensity therapy followed by allogeneic hematopoietic cell transplant (HCT).

Health professional · Treatment of AML in Remission

Chemotherapy

Source: Acute Myeloid Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: March 14, 2025. Captured 2026-09-09.

Nontransplant consolidation therapy using cytarabine-containing regimens has treatment-related death rates that are usually less than 10% to 20% and has reported long-term DFS rates from 20% to 50%.[3-6] The optimal doses, schedules, and duration of consolidation chemotherapy have not been determined.

Sources: 3 · 6

The standard consolidation therapy for AML patients in remission is high-dose cytarabine; however, there exists some controversy about whether it benefits all younger AML patients in first complete response versus selected subgroups, such as those with core-binding factor abnormalities.[7-11] The duration of consolidation therapy has ranged from one cycle [4,6] to four or more cycles.[3,5]

Sources: 7 · 11 · 4 · 6 · 3 · 5

Evidence (chemotherapy):

A large, randomized trial that compared three different cytarabine-containing consolidation therapy regimens showed a clear benefit in survival to patients younger than 60 years who received high-dose cytarabine.[3]

Sources: 3

Intensification of cytarabine dose or duration of consolidation chemotherapy with conventionally dosed cytarabine did not improve DFS or overall survival (OS) in patients aged 60 years or older, as evidenced in the Medical Research Council (MRC-LEUK-AML11) trial.[12,13]

Sources: 12 · 13

Dose-intensive cytarabine-based chemotherapy can be complicated by severe neurological [14] and/or pulmonary toxic effects [15] and should be administered by physicians experienced in these regimens at centers that are equipped to treat potential complications. In a retrospective analysis of 256 patients who received high-dose bolus cytarabine at a single institution, the most powerful predictor of cytarabine neurotoxicity was renal insufficiency. The incidence of neurotoxicity was significantly greater in patients treated with twice daily doses of 3 g/m2/dose when compared with 2 g/m2/dose.

Sources: 14 · 15

Health professional · Treatment of AML in Remission

Maintenance Therapy

Source: Acute Myeloid Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: March 14, 2025. Captured 2026-09-09.

While a number of older studies have included longer-term therapy at lower doses (maintenance), there has been no convincing evidence that maintenance therapy provides prolonged DFS or OS. However, maintenance therapy with midostaurin or oral azacitidine may improve outcomes.

Health professional · Treatment of AML in Remission / Maintenance Therapy

Midostaurin

Source: Acute Myeloid Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: March 14, 2025. Captured 2026-09-09.

Evidence (midostaurin):

Variants in the tyrosine kinase domain and internal tandem duplications of the FLT3 gene are frequent in AML and are often associated with an inferior outcome.

In the multicenter, randomized, phase III RATIFY trial (NCT00651261), the FLT3/multikinase inhibitor midostaurin plus cytarabine and daunorubicin induction chemotherapy was compared with placebo in patients with FLT3-altered AML.[16][Level of evidence A1]While maintenance was well tolerated in the RATIFY study, only a small subset of patients tolerated midostaurin as maintenance therapy after chemotherapy or transplant in a separate phase II study.[18]

Sources: RATIFY · 16 · Level of evidence A1 · 18

In the multicenter, randomized, phase III RATIFY trial (NCT00651261), the FLT3/multikinase inhibitor midostaurin plus cytarabine and daunorubicin induction chemotherapy was compared with placebo in patients with FLT3-altered AML.[16][Level of evidence A1]While maintenance was well tolerated in the RATIFY study, only a small subset of patients tolerated midostaurin as maintenance therapy after chemotherapy or transplant in a separate phase II study.[18]

The addition of the FLT3/multikinase inhibitor midostaurin to cytarabine and daunorubicin induction chemotherapy led to improved survival (median, 75 vs. 26 months; hazard ratio [HR] for death, 0.78; one-sided P = .009).

Patients who remained in remission after completion of consolidation therapy entered a maintenance phase in which they received midostaurin or placebo, administered at a dose of 50 mg orally twice daily, for twelve 28-day cycles. A maintenance regimen was administered for the full 12 cycles in 120 patients (69 in the midostaurin group, and 51 in the placebo group).

An ad-hoc landmark analysis from the end of maintenance revealed no difference in DFS between the two arms. Moreover, from the start of maintenance therapy there was no difference in OS between the two arms.[17]

Sources: 17

In the multicenter, randomized phase II RADIUS trial (NCT01883362), the addition of midostaurin to standard of care was compared with standard of care alone after allogeneic HCT.[19] Similar to the RATIFY trial, midostaurin was administered at a dose of 50 mg orally twice daily, for twelve 28-day cycles. Thirty patients were enrolled in each arm, but only half were able to complete the entire 12 cycles of therapy.

Sources: RADIUS · 19

In the multicenter, randomized phase II RADIUS trial (NCT01883362), the addition of midostaurin to standard of care was compared with standard of care alone after allogeneic HCT.[19] Similar to the RATIFY trial, midostaurin was administered at a dose of 50 mg orally twice daily, for twelve 28-day cycles. Thirty patients were enrolled in each arm, but only half were able to complete the entire 12 cycles of therapy.

The estimated 18-month relapse-free survival (RFS) rate was 89% in the midostaurin arm and 76% in the standard of care arm (HR, 0.46; 95% confidence interval [CI], 0.12−1.86; P = 0.27). The predicted relative reduction in the risk of relapse with the addition of midostaurin was 54%.[19][Level of evidence B1]

Sources: 19 · Level of evidence B1

Health professional · Treatment of AML in Remission / Maintenance Therapy

Oral azacitidine

Source: Acute Myeloid Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: March 14, 2025. Captured 2026-09-09.

Evidence (oral azacitidine):

The randomized, double-blind, placebo-controlled phase III QUAZAR AML-001 trial (NCT01757535) provided the basis for regulatory approval of oral azacitidine as maintenance therapy for AML.[20] The study included 472 patients with AML who were aged 55 years or older, were within 4 months of first CR or CR with incomplete hematologic recovery after induction chemotherapy with or without consolidation treatment, and were not candidates for allogeneic HCT. Oral azacitidine or placebo was administered at 300 mg daily for 14 days every 28 days. Treatment was continued until disease progression or unacceptable toxicity.

Sources: QUAZAR AML-001 · 20

The randomized, double-blind, placebo-controlled phase III QUAZAR AML-001 trial (NCT01757535) provided the basis for regulatory approval of oral azacitidine as maintenance therapy for AML.[20] The study included 472 patients with AML who were aged 55 years or older, were within 4 months of first CR or CR with incomplete hematologic recovery after induction chemotherapy with or without consolidation treatment, and were not candidates for allogeneic HCT. Oral azacitidine or placebo was administered at 300 mg daily for 14 days every 28 days. Treatment was continued until disease progression or unacceptable toxicity.

For patients who received azacitidine, the median OS from randomization was 24.7 months (95% CI, 18.7−30.5) compared with 14.8 months (95% CI, 11.7−17.6) for patients receiving placebo (HR, 0.69; 95% CI, 0.55−0.86; P = .0009).[20][Level of evidence A1]

Sources: 20 · Level of evidence A1

Health professional · Treatment of AML in Remission

Hematopoietic Cell (Bone Marrow or Stem Cell) Transplant

Source: Acute Myeloid Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: March 14, 2025. Captured 2026-09-09.

Health professional · Treatment of AML in Remission / Hematopoietic Cell (Bone Marrow or Stem Cell) Transplant

Allogeneic HCT

Source: Acute Myeloid Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: March 14, 2025. Captured 2026-09-09.

Allogeneic HCT, even with minimal conditioning chemotherapy, results in the lowest incidence of leukemic relapse, even when compared with HCT from an identical twin (syngeneic HCT). This finding led to the concept of an immunologic graft-versus-leukemia effect, similar to (and related to) graft-versus-host disease. The improvement in freedom from relapse using allogeneic HCT as the primary consolidation therapy is offset, at least in part, by the increased morbidity and mortality caused by graft-versus-host disease, veno-occlusive disease of the liver, and infection. The DFS rates using allogeneic transplant in first complete remission have ranged from 45% to 60%.[21-24]

Sources: 21 · 24

The use of allogeneic HCT in adults requires either a HLA-matched sibling donor, an HLA-matched unrelated donor, a haploidentical donor (“half HLA-matched”), or two well-matched umbilical cord blood units. Including patients who underwent HCT from 2007 to 2017, the 3-year probabilities of survival after HLA-matched sibling transplant were 59% (±1%) for patients with early disease, 53% (±1%) for patients with intermediate disease, and 29% (±1%) for patients with advanced disease, according to the Center for International Blood and Marrow Transplant Research registry.[24] The probabilities of survival after an unrelated donor transplant were 53% (±1%) for patients with early disease, 50% (±1%) for intermediate disease, and 27% (±1%) for patients with advanced disease. [Level of evidence C1]

Sources: 24 · Level of evidence C1

Because HCT can cure more than 30% of patients who experience relapse after chemotherapy, some investigators suggested that allogeneic bone marrow transplant (BMT) can be reserved for early first relapse or second CR without compromising the number of patients who are ultimately cured.[25] Clinical and cytogenetic information can define certain subsets of patients with predictable better or worse prognoses according to favorable- and adverse-risk factors in those using consolidation chemotherapy.[26]

Sources: 25 · 26

Favorable-risk AML: Favorable-risk factors include t(8;21), inv(16), normal karyotype with an NPM1 variant (in absence of an FLT3 variant), and normal karyotype with double cytosine-cytosine-adenosine-adenosine-thymidine (CCAAT)-enhancer binding protein (C/EBP)-alpha variants. Patients in the favorable-risk group have a reasonable chance of cure with intensive consolidation chemotherapy, and it may be reasonable to defer transplant in that group until early first relapse.

Adverse-risk AML: Adverse-risk factors include deletion of 5q, 7q, 17p, inversion of 3 or t(3;3), abnormality of (17p), trisomy 8, t(6;9), t(9;22), most translocations involving chromosome 11q23, KMT2A variants, a complex or monosomal karyotype, a history of myelodysplasia or antecedent hematologic disorder, TP53 variants, RUNX1 variants, ASXL1 variants, and normal karyotype with FLT3 variants. The adverse-risk group is highly unlikely to be cured with consolidation chemotherapy, and allogeneic BMT in first CR is a reasonable option for patients. However, even with allogeneic stem cell transplant, the outcome for patients with high-risk AML is poor (5-year DFS rate of 8% to 30% for patients with treatment-related leukemia or myelodysplasia).[27]

Sources: 27

Normal cytogenetics: Patients with normal cytogenetics are in an intermediate-risk group, and consolidation management should be individualized based on additional molecular markers, patient comorbid factors, and patient preference or, preferably, managed according to a clinical trial.

A common clinical trial design used to evaluate the benefit of allogeneic transplant as consolidation therapy for AML in first remission is the so-called donor-no donor comparison. In this design, newly diagnosed AML patients who achieve a CR are deemed medically eligible for allogeneic transplant and undergo HLA typing. If a matched sibling or matched unrelated donor is identified, the patient is allocated to the transplant arm. Analysis of outcome is by intention to treat; that is, patients assigned to the donor arm who do not receive a transplant are grouped in the analysis with the patients who did actually receive a transplant. RFS is the usual end point for this type of trial. OS from the time of diagnosis is less frequently reported in these trials.

Investigators attempted to address this issue with a meta-analysis using data from 18 separate prospective trials of AML patients using the donor-no donor design, with data from an additional six trials included for sensitivity analysis.[28] The trials included in this meta-analysis enrolled adult patients aged 60 years and younger from 1982 to 2006. Median follow-up ranged from 42 months to 142 months. Preparative regimens were similar among the different trials. Allogeneic transplant was compared with autologous transplant (six trials) or with a variety of consolidation chemotherapy regimens, with high-dose cytarabine being the most common.

Sources: 28

Treatment-related mortality ranged from 5% to 42% in the donor groups compared with 3% to 27% in the no-donor group.

Of 18 trials reporting RFS across all cytogenetic risk groups, the combined HR for overall RFS benefit with allogeneic transplant was 0.80, indicating a statistically significant reduction in death or relapse in a first CR.

Of the 15 trials reporting OS across all cytogenetic risk groups, the combined HR for OS was 0.90, again indicating a statistically significant reduction in death or relapse in a first CR.

In subgroup analysis according to cytogenetic risk , there was no RFS or OS benefit of allogeneic transplant for patients with favorable-risk AML (RFS: HR, 1.07; 95% CI, 0.83–1.38; P = .59; OS: HR, 1.06; 95% CI, 0.64–1.76; P = .81). However, a transplant benefit was seen for patients with intermediate (RFS: HR, 0.83; 95% CI, 0.74–0.93; P < .01; OS: HR, 0.84; 95% CI, 0.71–0.99; P = .03) or adverse-risk cytogenetics (RFS: HR, 0.73; 95% CI, 0.59–0.90; P < .01; OS: HR, 0.60; 95% CI, 0.40–0.90; P = .01).[28][Level of evidence B4] The conclusion from this meta-analysis was that allogeneic transplant from a sibling donor in a first CR is justified on the basis of improved RFS and OS for patients with intermediate- or adverse-risk, but not favorable-risk, cytogenetics.An important caveat to this analysis is that induction and consolidation strategies for AML among studies included in the meta-analysis were not uniform; nor were definitions of cytogenetic risk groups uniform. This may have resulted in inferior survival rates among chemotherapy-only treated patients.

Sources: 28 · Level of evidence B4

Most physicians who treat patients with leukemia agree that transplant should be offered to AML patients in first CR in the setting of adverse-risk cytogenetics and should not be offered to patients in first CR with favorable-risk cytogenetics.[26] However, older patients with favorable-risk AML who are unlikely to tolerate intensive cytarabine-based consolidation therapy can be considered for allogeneic HCT as consolidation therapy.[29]

Sources: 26 · 29

Health professional · Treatment of AML in Remission / Hematopoietic Cell (Bone Marrow or Stem Cell) Transplant

Autologous hematopoietic stem cell transplant

Source: Acute Myeloid Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: March 14, 2025. Captured 2026-09-09.

The role of autologous transplant for AML patients has diminished over time because of the improvements in the nonrelapse mortality associated with allogeneic HCT, as well as the advent of haploidentical and umbilical cord transplant expanding the potential donor pool so that nearly every patient has a donor.[30-33] Autologous HCT can yield DFS rates between 35% and 50% in patients with AML in first remission. Autologous HCT has also cured a smaller proportion of patients in second remission.[34-40] Treatment-related mortality rates of patients who have had autologous peripheral blood or marrow transplant range from 10% to 20%.

Sources: 30 · 33 · 34 · 40

Health professional

Treatment of Refractory or Recurrent AML

Source: Acute Myeloid Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: March 14, 2025. Captured 2026-09-09.

No standard treatment regimen exists for patients with refractory or recurrent acute myeloid leukemia (AML).[1,2]

Sources: 1 · 2

Treatment options for refractory or recurrent AML include:

Chemotherapy.

Sources: Chemotherapy

Chemotherapy.

Intensive salvage chemotherapy.

Sources: Intensive salvage chemotherapy

Reduced-intensity therapy, including targeted therapy.

Sources: Reduced-intensity therapy, including targeted therapy

Allogeneic hematopoietic cell transplant (HCT).

Sources: Allogeneic hematopoietic cell transplant (HCT)

Health professional · Treatment of Refractory or Recurrent AML

Chemotherapy

Source: Acute Myeloid Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: March 14, 2025. Captured 2026-09-09.

Health professional · Treatment of Refractory or Recurrent AML / Chemotherapy

Intensive salvage chemotherapy

Source: Acute Myeloid Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: March 14, 2025. Captured 2026-09-09.

A number of intensive salvage chemotherapy regimens have demonstrated efficacy in recurrent AML, including:

Health professional · Treatment of Refractory or Recurrent AML / Chemotherapy / Intensive salvage chemotherapy

Fludarabine, cytarabine, and filgrastim (FLAG)

Source: Acute Myeloid Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: March 14, 2025. Captured 2026-09-09.

FLAG has shown antileukemic activity in patients with relapsed and refractory AML.

Evidence (FLAG):

A multicenter phase II study included 83 patients with relapsed or refractory AML or de novo refractory anemia with excess blasts in transformation. The primary end point was the rate of complete remission (CR) achieved after one or two courses of FLAG induction chemotherapy.[3]

Sources: 3

A multicenter phase II study included 83 patients with relapsed or refractory AML or de novo refractory anemia with excess blasts in transformation. The primary end point was the rate of complete remission (CR) achieved after one or two courses of FLAG induction chemotherapy.[3]

In patients with relapsed leukemia whose first remission lasted for 6 months or more, the CR rate was 81% (17 of 21 patients).

In patients with AML whose first remission lasted less than 6 months, or in patients with primary refractory disease, the CR rate was 30% (13 of 44 patients).[3][Level of evidence C3]

Sources: 3 · Level of evidence C3

Myelosuppression and mucositis were common therapy-related toxicities.

Idarubicin has been added to this regimen as well (FLAG-Ida).[4]

Sources: 4

Health professional · Treatment of Refractory or Recurrent AML / Chemotherapy / Intensive salvage chemotherapy

Mitoxantrone, etoposide, and cytarabine (MEC)

Source: Acute Myeloid Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: March 14, 2025. Captured 2026-09-09.

Evidence (MEC):

A study evaluated one course of MEC chemotherapy in 74 patients with AML and a poor prognosis. The population included 30 patients with relapsed AML, 28 patients with primary refractory AML, and 16 patients with secondary AML.[5]

Sources: 5

A study evaluated one course of MEC chemotherapy in 74 patients with AML and a poor prognosis. The population included 30 patients with relapsed AML, 28 patients with primary refractory AML, and 16 patients with secondary AML.[5]

MEC demonstrated a CR induction rate of 55%.[5][Level of evidence C3]

Sources: 5 · Level of evidence C3

A phase III randomized Eastern Cooperative Oncology Group (ECOG) trial (E-2995) assessed 129 patients with one of the following disease statuses: relapsed AML less than 6 months after first CR; relapsed AML after allogeneic or autologous bone marrow transplant; second or greater AML relapse; primary induction failure; secondary AML; or high-risk myelodysplastic syndromes. Patients were randomly assigned to receive MEC with or without valspodar, a multidrug resistance modulator.

A phase III randomized Eastern Cooperative Oncology Group (ECOG) trial (E-2995) assessed 129 patients with one of the following disease statuses: relapsed AML less than 6 months after first CR; relapsed AML after allogeneic or autologous bone marrow transplant; second or greater AML relapse; primary induction failure; secondary AML; or high-risk myelodysplastic syndromes. Patients were randomly assigned to receive MEC with or without valspodar, a multidrug resistance modulator.

The complete response rate was only 17% to 25% in both arms.[6][Level of evidence B3]

Sources: 6 · Level of evidence B3

Health professional · Treatment of Refractory or Recurrent AML / Chemotherapy / Intensive salvage chemotherapy

Standard or high-dose cytarabine and mitoxantrone

Source: Acute Myeloid Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: March 14, 2025. Captured 2026-09-09.

Evidence (standard or high-dose cytarabine and mitoxantrone):

A study of cytarabine and mitoxantrone included 49 patients with relapsed or refractory AML.[7]

Sources: 7

A study of cytarabine and mitoxantrone included 49 patients with relapsed or refractory AML.[7]

Treatment was successful in 50% to 60% of patients who experienced relapse after initially obtaining a CR, with 62.5% of patients with AML in first relapse achieving M1 marrow.[7,8]

Sources: 7 · 8

Health professional · Treatment of Refractory or Recurrent AML / Chemotherapy / Intensive salvage chemotherapy

High-dose etoposide and cyclophosphamide

Source: Acute Myeloid Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: March 14, 2025. Captured 2026-09-09.

Evidence (high-dose etoposide and cyclophosphamide):

Reported results have been similar to those for the combination of cytarabine and mitoxantrone.[9]

Sources: 9

Health professional · Treatment of Refractory or Recurrent AML / Chemotherapy / Intensive salvage chemotherapy

Idarubicin and cytarabine

Source: Acute Myeloid Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: March 14, 2025. Captured 2026-09-09.

Evidence (idarubicin and cytarabine):

Reported results have been similar to those for the combination of cytarabine and mitoxantrone.[10,11]

Sources: 10 · 11

Health professional · Treatment of Refractory or Recurrent AML / Chemotherapy / Intensive salvage chemotherapy

Other intensive regimens

Source: Acute Myeloid Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: March 14, 2025. Captured 2026-09-09.

High-dose cytarabine.[12]

Sources: 12

Cytarabine, daunorubicin, and etoposide (ADE).[13]

Sources: 13

Clofarabine plus cytarabine with or without filgrastim (CLAG).[14,15]

Sources: 14 · 15

Health professional · Treatment of Refractory or Recurrent AML / Chemotherapy

Reduced-intensity therapy, including targeted therapy

Source: Acute Myeloid Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: March 14, 2025. Captured 2026-09-09.

Patients who are unable or unwilling to undergo intensive therapy can be treated with reduced-intensity therapies.

Health professional · Treatment of Refractory or Recurrent AML / Chemotherapy / Reduced-intensity therapy, including targeted therapy

Gilteritinib

Source: Acute Myeloid Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: March 14, 2025. Captured 2026-09-09.

Gilteritinib is an oral FLT3 inhibitor with activity in both internal tandem duplication (ITD) and tyrosine kinase domain (TKD) subtypes.

Evidence (gilteritinib):

In a phase III trial, 371 patients were randomly assigned in a 2:1 ratio to receive either gilteritinib or preselected salvage chemotherapy (MEC, FLAG-Ida, azacitidine, or low-dose cytarabine).[16,17]

Sources: 16 · 17

In a phase III trial, 371 patients were randomly assigned in a 2:1 ratio to receive either gilteritinib or preselected salvage chemotherapy (MEC, FLAG-Ida, azacitidine, or low-dose cytarabine).[16,17]

With a median follow-up of 37.1 months, the median overall survival (OS) was 9.3 months for patients who received gilteritinib versus 5.6 months for patients who received chemotherapy (hazard ratio [HR] for death, 0.665; 95% confidence interval [CI], 0.52–0.85). The estimated OS rate at 2 years was 20.6% (95% CI, 15.8%–26.0%) for patients who received gilteritinib and 14.2% (95% CI, 8.3%–21.6%) for patients who received chemotherapy.[16] Among those treated with gilteritinib, the median duration of complete response or complete response with partial hematologic recovery was 10 months (interquartile range [IQR], 2.08–not evaluable), and 23 months (IQR, 4.9–not evaluable) for just those achieving a complete response.[17]

Sources: 16 · 17

The rates of complete response and complete response with partial hematologic recovery were higher in patients who received gilteritinib than in patients who received chemotherapy (34% vs. 15.3%; HR, 18.6; 95% CI, 9.8–27.4).

Adverse events of grade 3 or higher were less common in patients who received gilteritinib when adjusted for exposure time.[16][Level of evidence A1] The most common adverse event of interest was increased liver transaminases for patients who received gilteritinib therapy. If liver transaminase levels (considered related to treatment) increase to more than 5 times the upper limit of normal, gilteritinib therapy is paused. When the enzymes return to less than 2.5 times the upper limit of normal, therapy can resume at a reduced dose of 80 mg once daily.[17][Level of evidence A1]

Sources: 16 · Level of evidence A1 · 17 · Level of evidence A1

Health professional · Treatment of Refractory or Recurrent AML / Chemotherapy / Reduced-intensity therapy, including targeted therapy

Enasidenib

Source: Acute Myeloid Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: March 14, 2025. Captured 2026-09-09.

Enasidenib is an oral small molecule inhibitor with activity against the altered IDH2 enzyme.

Evidence (enasidenib):

In a phase I/II study, 214 patients with relapsed or refractory AML were treated with enasidenib.[18]

Sources: 18

In a phase I/II study, 214 patients with relapsed or refractory AML were treated with enasidenib.[18]

The overall response rate was 40.3% (95% CI, 33.0%–48.0%), with a median response duration of 5.8 months.

This included 46 patients (26.1%) with a CR or a CR with incomplete hematologic recovery (CRi).

Grade 3 or 4 treatment-related adverse events included indirect hyperbilirubinemia (12%) and differentiation syndrome (7%). As a result, the U.S. Food and Drug Administration (FDA) added a boxed warning to enasidenib, which alerts prescribers that differentiation syndrome can occur.[18][Level of evidence C3]

Sources: boxed warning · 18 · Level of evidence C3

Health professional · Treatment of Refractory or Recurrent AML / Chemotherapy / Reduced-intensity therapy, including targeted therapy

Ivosidenib

Source: Acute Myeloid Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: March 14, 2025. Captured 2026-09-09.

Ivosidenib is an oral small molecule inhibitor with activity against the altered IDH1 enzyme.

Evidence (ivosidenib):

In a phase I/II study, 179 patients with relapsed or refractory AML were treated with ivosidenib.[19]

Sources: 19

In a phase I/II study, 179 patients with relapsed or refractory AML were treated with ivosidenib.[19]

The overall response rate was 39.1% (95% CI, 31.9%–46.7%) with a median duration response of 6.5 months (range, 4.6–9.3). This included 54 patients (30.2%) with a CR or a CRi.

Over one-third of patients who initially required transfusions became transfusion independent.

Grade 3 or higher prolongation of the QT interval was seen in 14 patients (7.8%), and grade 3 or higher differentiation was seen in 7 patients (3.9%). The FDA added a boxed warning to ivosidenib, which alerts prescribers that differentiation syndrome can occur.[19][Level of evidence C3]

Sources: boxed warning · 19 · Level of evidence C3

Health professional · Treatment of Refractory or Recurrent AML / Chemotherapy / Reduced-intensity therapy, including targeted therapy

Revumenib

Source: Acute Myeloid Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: March 14, 2025. Captured 2026-09-09.

Revumenib is an oral menin inhibitor that is approved by the FDA for the treatment of relapsed or refractory acute leukemia with a KMT2A translocation in adult and pediatric patients aged 1 year and older.

In the phase I/II AUGMENT-101 study (NCT04065399), 104 patients with relapsed or refractory acute leukemia with a KMT2A rearrangement received revumenib. Patients had to have a corrected QT interval (QTc) using Fridericia's formula of less than 450 milliseconds at baseline.[20]

Sources: AUGMENT-101 · 20

In the phase I/II AUGMENT-101 study (NCT04065399), 104 patients with relapsed or refractory acute leukemia with a KMT2A rearrangement received revumenib. Patients had to have a corrected QT interval (QTc) using Fridericia's formula of less than 450 milliseconds at baseline.[20]

The overall rate of CR plus CRh (complete remission with partial hematologic recovery) was 21.2% (95% CI, 13.8%–30.3%). The median duration of CR plus CRh was 6.4 months (95% CI, 2.7–not reached).[20][Level of evidence C3]

Sources: 20 · Level of evidence C3

Of the 83 patients who were dependent on red blood cell and/or platelet transfusions, 14% became independent of transfusions during a 56-day postbaseline period.

Revumenib has a boxed warning for differentiation syndrome, which was observed in 29% of patients. Grade 3 or 4 differentiation syndrome was observed in 13% of patients, and one patient died (0.7%).

Sources: boxed warning

Grade 3 or higher QTc prolongation was observed in 12% of patients.

Because revumenib is metabolized by CYP3A4, the dose must be reduced in patients receiving strong CYP3A4 inhibitors. The standard dose for patients who weigh more than 40 kg is 270 mg orally twice daily, with a dose reduction to 160 mg orally twice daily for patients receiving a strong CYP3A4 inhibitor. Furthermore, the dose is adjusted according to body surface area in patients who weigh less than 40 kg.

Health professional · Treatment of Refractory or Recurrent AML / Chemotherapy / Reduced-intensity therapy, including targeted therapy

Hypomethylating agents

Source: Acute Myeloid Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: March 14, 2025. Captured 2026-09-09.

Evidence (hypomethylating agents):

In a retrospective analysis, 655 patients with relapsed or primary treatment-refractory AML received either azacitidine (57%) or decitabine (43%).[21]

Sources: 21

In a retrospective analysis, 655 patients with relapsed or primary treatment-refractory AML received either azacitidine (57%) or decitabine (43%).[21]

Overall, 16% of patients achieved a CR or a CRi and experienced a median OS of 21 months.[21][Level of evidence C3]

Sources: 21 · Level of evidence C3

Health professional · Treatment of Refractory or Recurrent AML / Chemotherapy / Reduced-intensity therapy, including targeted therapy

Gemtuzumab ozogamicin

Source: Acute Myeloid Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: March 14, 2025. Captured 2026-09-09.

The antibody-targeted chemotherapy agent gemtuzumab ozogamicin has been evaluated in patients who had relapsed AML and expressed CD33.

Evidence (gemtuzumab ozogamicin):

A pooled analysis of three open-label, single-arm, phase II studies included 277 patients.[22]

Sources: 22

A pooled analysis of three open-label, single-arm, phase II studies included 277 patients.[22]

The overall response rate was 26%. Thirty-five patients (13%) achieved a CR and 36 patients (13%) achieved a CR without platelet recovery. It is unclear whether the inadequate platelet recovery was the result of megakaryocyte toxic effects of gemtuzumab or subclinical residual leukemia. [22]

Sources: 22

The long-term outcomes of patients who receive gemtuzumab and achieve CR without platelet recovery are unclear. Gemtuzumab induces profound bone marrow aplasia similar to leukemia induction chemotherapy and also has substantial hepatic toxic effects, including hepatic veno-occlusive disease.[22][Level of evidence C3]

Sources: 22 · Level of evidence C3

Health professional · Treatment of Refractory or Recurrent AML / Chemotherapy / Reduced-intensity therapy, including targeted therapy

Clofarabine with or without cytarabine

Source: Acute Myeloid Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: March 14, 2025. Captured 2026-09-09.

Evidence (clofarabine with or without cytarabine):

Clofarabine, a purine nucleoside analogue, was studied as a single agent in 62 patients with relapsed or refractory AML.[23]

Sources: 23

Clofarabine, a purine nucleoside analogue, was studied as a single agent in 62 patients with relapsed or refractory AML.[23]

Eight of 19 patients who received treatment for their first relapse experienced a complete response.

Clofarabine was administered in combination with intermediate-dose cytarabine in patients with relapsed or refractory AML.[24]

Sources: 24

Clofarabine was administered in combination with intermediate-dose cytarabine in patients with relapsed or refractory AML.[24]

Seven of 29 patients with AML or myelodysplastic syndrome who received treatment for their first relapse had a CR.[24][Level of evidence C3]

Sources: 24 · Level of evidence C3

Health professional · Treatment of Refractory or Recurrent AML

Allogeneic Hematopoietic Cell Transplant

Source: Acute Myeloid Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: March 14, 2025. Captured 2026-09-09.

When patients with relapsed disease are treated aggressively, they may have extended disease-free survival (DFS); however, patients with relapsed disease can only be cured with HCT.[25][Level of evidence C2] Allogeneic HCT for patients in their second CR provides better DFS rates than transplant for patients in relapse.[26][Level of evidence C1]

Sources: 25 · Level of evidence C2 · 26 · Level of evidence C1

Evidence (allogeneic HCT):

Current transplant outcomes are reported by the Center for International Blood and Marrow Transplantation Registry. The group reported the following outcomes for transplants done in the United States between 2008 and 2018:[27][Level of evidence C2]

Sources: 27 · Level of evidence C2

Current transplant outcomes are reported by the Center for International Blood and Marrow Transplantation Registry. The group reported the following outcomes for transplants done in the United States between 2008 and 2018:[27][Level of evidence C2]

The 3-year survival rate was 53% for patients with AML in second or subsequent CR versus 31% for patients with relapsed disease (or never in a CR) who underwent a matched sibling donor transplant.

The 3-year survival rate was 50% for patients with AML in second or subsequent CR versus 30% for patients with relapsed disease (or who never achieved CR) who underwent a matched unrelated donor transplant.

Allogeneic HCT can be effective salvage therapy in some patients whose disease fails to go into remission with intensive chemotherapy (primary refractory leukemia). A number of retrospective studies have demonstrated the ability of allogeneic HCT to induce remission in primary refractory disease.[28]

Sources: 28

Evidence (allogeneic HCT to induce remission):

In one retrospective analysis of 168 patients with AML and primary refractory disease who underwent allogeneic HCT, the 5-year OS rate was 22%.[29]

Sources: 29

Another analysis was conducted among patients enrolled in a prospective cooperative group trial, SWOG S0106 (NCT00085709).[30]

Sources: SWOG S0106 · 30

Another analysis was conducted among patients enrolled in a prospective cooperative group trial, SWOG S0106 (NCT00085709).[30]

Of the 589 patients treated in the cooperative group trial, 150 (25%) had primary refractory disease.

Among the 64 patients with primary refractory disease who received an allogeneic HCT, the 4-year survival rate was 48% compared with 4% among the 86 patients who did not undergo transplant.[30][Level of evidence C3]

Sources: 30 · Level of evidence C3

Randomized trials testing the efficacy of this approach are not available.

Health professional

Treatment of Acute Promyelocytic Leukemia (APL)

Source: Acute Myeloid Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: March 14, 2025. Captured 2026-09-09.

Special consideration must be given to induction therapy for APL. Treatment is centered around the use of differentiating agents to clear the leukemic cells. Early mortality is related to bleeding, differentiation syndrome, or infection. High complete remission (CR) rates are very common across treatment regimens, and persistent disease or relapse is rare.

Health professional · Treatment of Acute Promyelocytic Leukemia (APL)

Treatment of Newly Diagnosed APL

Source: Acute Myeloid Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: March 14, 2025. Captured 2026-09-09.

Treatment options for newly diagnosed APL include:

All-trans retinoic acid (ATRA) plus arsenic trioxide (ATO) for low- to intermediate-risk disease.

Sources: All-trans retinoic acid (ATRA) plus arsenic trioxide (ATO) for low- to intermediate-risk disease

ATRA plus chemotherapy, followed by ATO-based consolidation therapy for high-risk disease.

Sources: ATRA plus chemotherapy, followed by ATO-based consolidation therapy for high-risk disease

ATRA induces terminal differentiation of the leukemic cells followed by restoration of nonclonal hematopoiesis. Administration of ATRA leads to rapid resolution of coagulopathy in most patients, and heparin administration is not required in patients receiving ATRA. However, randomized trials have not shown a reduction in morbidity and mortality during ATRA induction when compared with chemotherapy. ATRA administration may result in the following conditions:

Differentiation syndrome: Administration of ATRA can lead to a syndrome of respiratory distress, known as differentiation syndrome. Prompt recognition of the syndrome and aggressive administration of steroids can prevent severe respiratory distress.[1]

Sources: 1

Hyperleukocytosis: The optimal management of ATRA-induced hyperleukocytosis has not been established. Hyperleukocytosis in APL is typically treated with the addition of cytotoxic chemotherapy. Leukopheresis is not recommended because of an increased risk of complications such as bleeding events and disseminated intravascular coagulation.

Studies performed in the 1990s demonstrated that overall survival (OS) rates improved in patients receiving ATRA in addition to chemotherapy.[2,3] ATO, an agent with both differentiation-inducing and apoptosis-inducing properties against APL cells, is also used in the treatment of APL. Induction remission therapy for APL is determined by disease risk. Low- to intermediate-risk APL (white blood cell [WBC] count ≤10 × 109/L) is treated without chemotherapy (ATRA and ATO), and high-risk is treated with a combination of ATRA and ATO plus chemotherapy.

Sources: 2 · 3

Health professional · Treatment of Acute Promyelocytic Leukemia (APL) / Treatment of Newly Diagnosed APL

ATRA plus ATO for low- to intermediate-risk disease

Source: Acute Myeloid Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: March 14, 2025. Captured 2026-09-09.

Evidence (ATRA plus ATO for low- to intermediate-risk disease):

In a phase III, randomized controlled, multicenter trial in patients with APL classified as low-to-intermediate risk (WBC count, ≤10 × 109/L) ATRA plus chemotherapy was compared with ATRA plus ATO.[4]

Sources: 4

In a phase III, randomized controlled, multicenter trial in patients with APL classified as low-to-intermediate risk (WBC count, ≤10 × 109/L) ATRA plus chemotherapy was compared with ATRA plus ATO.[4]

CR rates were equally high for both groups. CR occurred in all 77 patients (100%) who could be evaluated in the ATRA plus ATO group and in 75 of 79 patients (95%) in the ATRA plus chemotherapy group (P = .12).

With a median follow-up of 34.4 months, the 2-year OS rate was 99% (95% confidence interval [CI], 96%−100%) in the ATRA plus ATO group, and 91% (95% CI, 85%−97%) in the ATRA plus chemotherapy group (P = .02).

The 2-year cumulative incidence of relapse was similarly low in both groups, 1% (95% CI, 0%−4%) in the ATRA plus ATO group and 6% (95% CI, 0%−11%) in the ATRA plus chemotherapy group (P = .24).

The primary end point was event-free survival (EFS) (defined as no achievement of hematologic CR after induction therapy, no achievement of molecular CR after three consolidation courses, molecular relapse, hematologic relapse, or death). The 2-year EFS rate was 97% for the ATRA plus ATO group and 85% in the ATRA plus chemotherapy group (P < .001 for noninferiority).

The results of this chemotherapy-free regimen for low- to intermediate-risk APL were confirmed in a second, phase III, randomized controlled trial.[5][Level of evidence A1]

Sources: 5 · Level of evidence A1

Health professional · Treatment of Acute Promyelocytic Leukemia (APL) / Treatment of Newly Diagnosed APL

ATRA plus chemotherapy, followed by ATO-based consolidation therapy for high-risk disease

Source: Acute Myeloid Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: March 14, 2025. Captured 2026-09-09.

Remission induction with a combination of anthracycline and ATRA is used for remission induction in patients with high-risk disease (WBC count, >10 × 109/L).

Evidence (ATRA plus chemotherapy, followed by ATO-based consolidation therapy for high-risk disease):

The AIDA-2000 study (NCT00180128) combined oral ATRA until CR or for a maximum of 45 days and four doses of intravenous idarubicin (12 mg/m2) on days 2, 4, 6, and 8. Consolidation was then risk stratified so low- to intermediate-risk patients received additional cycles of anthracycline and ATRA, and high-risk patients also received cytarabine, etoposide, 6-thioguanine, and CHT chemotherapy (6-mercaptopurine plus methotrexate) as consolidation.[6]

Sources: AIDA-2000 · 6

The AIDA-2000 study (NCT00180128) combined oral ATRA until CR or for a maximum of 45 days and four doses of intravenous idarubicin (12 mg/m2) on days 2, 4, 6, and 8. Consolidation was then risk stratified so low- to intermediate-risk patients received additional cycles of anthracycline and ATRA, and high-risk patients also received cytarabine, etoposide, 6-thioguanine, and CHT chemotherapy (6-mercaptopurine plus methotrexate) as consolidation.[6]

After induction, 420 of 445 patients (94.4%) treated on the AIDA-2000 protocol were in CR. The 6-year OS rate was 87.4% and the cumulative incidence of relapse rate was 10.7%.[6][Level of evidence B4]

Sources: 6 · Level of evidence B4

In the phase II APML4 study, ATO was added to the ATRA-and-idarubicin remission−induction backbone.[7] An ATO-based regimen, which includes gemtuzumab ozogamicin as the only cytotoxic drug, has been developed.

Sources: 7

In the phase II APML4 study, ATO was added to the ATRA-and-idarubicin remission−induction backbone.[7] An ATO-based regimen, which includes gemtuzumab ozogamicin as the only cytotoxic drug, has been developed.

Of the 124 patients who could be evaluated, there were 4 (3.2%) early deaths and 118 (95%) hematologic CRs.

The 2-year freedom-from-relapse rate was 97.5% (95% CI, 90.4%−99.4%), the failure-free survival rate was 88.1% (95% CI, 80.7%−92.8%), and the OS rate was 93.2% (95% CI, 85.8%−96.8%).[7][Level of evidence B4]

Sources: 7 · Level of evidence B4

In a single-institution study, patients received ATRA plus ATO induction. They also received a dose of gemtuzumab ozogamicin (or idarubicin) if the WBC was greater than 10 × 109/L on presentation or rose to more than 30 × 109/L during induction.[8] Patients in remission received ATO and ATRA in alternating months for a total of seven cycles as consolidation; gemtuzumab ozogamicin was substituted if either ATO or ATRA were discontinued because of toxicity. Long-term follow up from this study has been published.[9]

Sources: 8 · 9

In a single-institution study, patients received ATRA plus ATO induction. They also received a dose of gemtuzumab ozogamicin (or idarubicin) if the WBC was greater than 10 × 109/L on presentation or rose to more than 30 × 109/L during induction.[8] Patients in remission received ATO and ATRA in alternating months for a total of seven cycles as consolidation; gemtuzumab ozogamicin was substituted if either ATO or ATRA were discontinued because of toxicity. Long-term follow up from this study has been published.[9]

Of the 54 patients with high-risk disease treated on the protocol, one patient received both gemtuzumab ozogamicin and idarubicin (12 mg/m2 daily for 3 days) because of persistent leukocytosis despite receiving gemtuzumab ozogamicin.

The CR rate was 96%, and five (9%) patients relapsed.

The 5-year rates were 81% for EFS, 89% for disease-free survival (DFS), and 86% for OS, indicating that the responses are durable.

Across the entire study population, the 5-year OS rate was similar among the 45 high-risk patients who received gemtuzumab ozogamicin (84%) compared with the seven patients who received a dose of idarubicin (100%, P = .453).[8][Level of evidence B4]

Sources: 8 · Level of evidence B4

It is important to note that most current regimens for the treatment of APL include some form of maintenance therapy. A meta-analysis of randomized trials has indicated that maintenance clearly improves DFS but not OS; however, these trials did not include ATO-containing regimens.

Health professional · Treatment of Acute Promyelocytic Leukemia (APL)

Treatment of Recurrent APL

Source: Acute Myeloid Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: March 14, 2025. Captured 2026-09-09.

Treatment options for recurrent APL include:

ATO with or without chemotherapy.

Sources: ATO with or without chemotherapy

Hematopoietic cell transplant (HCT).

Sources: Hematopoietic cell transplant (HCT)

Health professional · Treatment of Acute Promyelocytic Leukemia (APL) / Treatment of Recurrent APL

ATO with or without chemotherapy

Source: Acute Myeloid Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: March 14, 2025. Captured 2026-09-09.

ATO has high rates of second remission in patients with relapsed APL.[10] As a single agent, ATO can lead to complete response rates of 80% to 90% in patients with hematologic relapse, and 70% to 80% in patients with molecular remission.[11-14] The choice of salvage therapy is based on the previous therapy and interval of time between first remission and relapse.

Sources: 10 · 11 · 14

In patients with early relapse less than 6 months after ATRA and ATO, anthracycline-based regimens and ATRA as given for initial remission induction for high-risk disease should be considered.

In patients who relapse less than 6 months after ATRA and anthracycline-based regimens (no previous ATO exposure), ATO-based regimens should be considered.

In all patients with late relapse (>6 months), ATO-based regimens with or without anthracycline or gemtuzumab ozogamicin should be considered.

For patients receiving ATO as salvage therapy, a small randomized trial suggested that the addition of ATRA does not confer any benefit over ATO alone in patients who previously received ATRA.[14] In this 20-patient study, the complete response rate after one cycle of ATO with or without ATRA was 80%.

Sources: 14

Health professional · Treatment of Acute Promyelocytic Leukemia (APL) / Treatment of Recurrent APL

HCT

Source: Acute Myeloid Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: March 14, 2025. Captured 2026-09-09.

Some patients in second remission with ATO have experienced long-term DFS after autologous stem cell transplant,[15,16] and it can be considered in patients who are in molecular remission (negative quantitative polymerase chain reaction [PCR] on a marrow sample). Patients who do not go into remission or have evidence of measurable residual disease by quantitative PCR on a marrow sample after salvage therapy are considered for an allogeneic HCT.[17] A registry study reported a 3-year OS rate after transplant in second CR of 80% compared with 59% in patients without transplant (P = .03).[10]

Sources: 15 · 16 · 17 · 10

For patients · General Information About Acute Myeloid Leukemia

Smoking, previous chemotherapy treatment, and exposure to radiation may increase the risk of AML.

Source: Acute Myeloid Leukemia Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: May 16, 2025. Captured 2026-09-09.

AML is caused by certain changes to the way blood stem cells function, especially how they grow and divide into new cells. A risk factor is anything that increases the chance of getting a disease. Some risk factors for AML, like smoking, can be changed. However, risk factors also include things people cannot change, like their genetics, getting older, and their health history.

There are many risk factors for AML, but many do not directly cause cancer. Instead, they increase the chance of DNA damage in cells that may lead to AML. Learn more about how cancer develops at What Is Cancer?

Sources: DNA · What Is Cancer?

Having one or more of these risk factors does not mean that you will get AML. Many people with risk factors never develop AML, while others with no known risk factors do.

Possible risk factors for AML include:

being male

older age

smoking

having had treatment with chemotherapy or radiation therapy in the past

Sources: chemotherapy · radiation therapy

being exposed to radiation in the environment (such as nuclear radiation) or to the chemical benzene

Sources: radiation · benzene

having a personal history of a blood disorder such as myelodysplastic syndrome

Sources: personal history · myelodysplastic syndrome

having certain syndromes or inherited disorders

Sources: syndromes · inherited

Talk with your doctor if you think you may be at risk.

For patients · General Information About Acute Myeloid Leukemia

Certain factors affect prognosis (chance of recovery) and treatment options.

Source: Acute Myeloid Leukemia Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: May 16, 2025. Captured 2026-09-09.

The prognosis and treatment options for AML depend on:

Sources: prognosis

the person's age

whether the leukemia has spread to the CNS

whether the patient has a systemic infection at the time of diagnosis

Sources: systemic · infection

whether the patient has a very high white blood cell count at the time of diagnosis

the subtype of AML

whether the patient received chemotherapy or radiation therapy in the past to treat a different cancer

whether there is a history of a blood disorder such as myelodysplastic syndrome

whether the cancer has been treated before or recurred (come back)

Sources: recurred

It is important to treat AML right away. Older age at diagnosis may be linked to lower remission rates and more complications.

Sources: remission · complications

For patients

Treatment Option Overview

Source: Acute Myeloid Leukemia Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: May 16, 2025. Captured 2026-09-09.

For patients · Treatment Option Overview

Key Points

Source: Acute Myeloid Leukemia Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: May 16, 2025. Captured 2026-09-09.

There are different types of treatment for people with acute myeloid leukemia (AML).

The treatment of AML usually has two phases.

Patients receive supportive care for side effects of treatment.

The following types of treatment are used:

The following types of treatment are used:

Chemotherapy

Radiation therapy

Chemotherapy with stem cell transplant

Targeted therapy

Other drug therapy

New types of treatment are being tested in clinical trials.

Treatment for acute myeloid leukemia may cause side effects.

Follow-up care may be needed.

For patients · Treatment Option Overview

There are different types of treatment for people with acute myeloid leukemia (AML).

Source: Acute Myeloid Leukemia Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: May 16, 2025. Captured 2026-09-09.

Different types of treatments are available for people with AML. You and your cancer care team will work together to decide your treatment plan, which may include more than one type of treatment. Many factors will be considered, such as the phase of the cancer, your overall health, and your preferences. Your plan will include information about your cancer, the goals of treatment, your treatment options and the possible side effects, and the expected length of treatment.

Talking with your cancer care team before treatment begins about what to expect will be helpful. You'll want to learn what you need to do before treatment begins, how you'll feel while going through it, and what kind of help you will need. Learn more at Questions to Ask Your Doctor about Treatment.

Sources: Questions to Ask Your Doctor about Treatment

For patients · Treatment Option Overview

The treatment of AML usually has two phases.

Source: Acute Myeloid Leukemia Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: May 16, 2025. Captured 2026-09-09.

There are two treatment phases of AML:

Remission induction therapy is the first phase of treatment. The goal is to kill the leukemia cells in the blood and bone marrow. This puts the leukemia into remission.

Sources: Remission induction therapy · leukemia cells · bone marrow · remission

Consolidation therapy is the second phase of treatment. It begins after the leukemia is in remission. The goal of consolidation therapy is to kill any remaining leukemia cells that may not be active but could begin to regrow and cause a relapse. This phase is also called remission continuation therapy.

Sources: Consolidation therapy · relapse

For patients · Treatment Option Overview

Patients receive supportive care for side effects of treatment.

Source: Acute Myeloid Leukemia Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: May 16, 2025. Captured 2026-09-09.

Patients must be closely monitored during treatment of AML. Myelosuppression, a condition which results in fewer red blood cells, white blood cells, and platelets, is a side effect of both AML and treatment with chemotherapy. Supportive care during remission induction therapy may include:

Sources: Myelosuppression · red blood cells · white blood cells · platelets · side effect · chemotherapy · Supportive care

red blood cell and platelet transfusions to replace blood cells destroyed by the cancer or its treatment

Sources: transfusions

antibiotics and antifungals to prevent or treat infections

Sources: antibiotics · antifungals · infections

For patients · Treatment Option Overview

The following types of treatment are used:

Source: Acute Myeloid Leukemia Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: May 16, 2025. Captured 2026-09-09.

For patients · Treatment Option Overview / The following types of treatment are used:

Chemotherapy

Source: Acute Myeloid Leukemia Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: May 16, 2025. Captured 2026-09-09.

Chemotherapy (also called chemo) uses drugs to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. The way the chemotherapy is given depends on the subtype of AML being treated and whether the leukemia cells have spread to the central nervous system (CNS; brain and spinal cord).

Sources: subtype

Systemic chemotherapy is when chemotherapy drugs are taken by mouth or injected into a vein or muscle. When given this way, the drugs enter the bloodstream and can reach cancer cells throughout the body.

Sources: injected

Systemic chemotherapy drugs used to treat AML include:

azacitidine

Sources: azacitidine

cytarabine

Sources: cytarabine

daunorubicin

Sources: daunorubicin

daunorubicin and cytarabine

Sources: daunorubicin and cytarabine

decitabine

Sources: decitabine

idarubicin

Sources: idarubicin

midostaurin

Sources: midostaurin

mitoxantrone

Sources: mitoxantrone

Combinations of these drugs may be used. Other chemotherapy drugs not listed here may also be used.

Intrathecal chemotherapy may be used to treat AML that has spread to the CNS (brain and spinal cord). Intrathecal chemotherapy is a method of placing chemotherapy directly into the cerebrospinal fluid, which is the fluid that surrounds the brain and spinal cord. This approach is used because the blood-brain barrier, a protective layer around the brain, can prevent chemotherapy drugs given by mouth or into a vein from reaching the CNS.

Cytarabine and methotrexate are two chemotherapy drugs given as intrathecal chemotherapy to treat AML. These drugs can also be given systemically.

Sources: methotrexate

Learn more about how chemotherapy works, how it is given, common side effects, and more at Chemotherapy to Treat Cancer and Chemotherapy and You: Support for People With Cancer.

Sources: Chemotherapy to Treat Cancer · Chemotherapy and You: Support for People With Cancer

For patients · Treatment Option Overview / The following types of treatment are used:

Radiation therapy

Source: Acute Myeloid Leukemia Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: May 16, 2025. Captured 2026-09-09.

Radiation therapy uses high-energy x-rays or other types of radiation to kill cancer cells or keep them from growing. AML is sometimes treated with external radiation therapy. This type of radiation therapy uses a machine outside the body to send radiation toward the area of the body with cancer. Total-body irradiation sends radiation toward the whole body. It is a type of external radiation that may be used to prepare the body for a stem cell transplant when the leukemia has recurred.

Sources: x-rays · radiation · external radiation therapy · Total-body irradiation · stem cell transplant · recurred

Learn more about External Beam Radiation Therapy for Cancer and Radiation Therapy Side Effects.

Sources: External Beam Radiation Therapy for Cancer · Radiation Therapy Side Effects

For patients · Treatment Option Overview / The following types of treatment are used:

Chemotherapy with stem cell transplant

Source: Acute Myeloid Leukemia Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: May 16, 2025. Captured 2026-09-09.

High doses of chemotherapy are given to kill cancer cells. Healthy cells, including blood-forming cells, are also destroyed by the cancer treatment. Stem cell transplant is a treatment to replace the blood-forming cells. Stem cells (immature blood cells) are removed from the blood or bone marrow of the patient or a donor and are frozen and stored. After the patient completes chemotherapy and/or total-body irradiation, the stored stem cells are thawed and given back to the patient through an infusion. These reinfused stem cells grow into (and restore) the body's blood cells.

Sources: Stem cells · bone marrow · donor · infusion

Learn more about Stem Cell Transplants in Cancer Treatment.

Sources: Stem Cell Transplants in Cancer Treatment

For patients · Treatment Option Overview / The following types of treatment are used:

Targeted therapy

Source: Acute Myeloid Leukemia Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: May 16, 2025. Captured 2026-09-09.

Targeted therapy uses drugs or other substances to identify and attack specific cancer cells. Your doctor may suggest biomarker tests to help predict your response to certain targeted therapy drugs. Learn more about Biomarker Testing for Cancer Treatment.

Sources: biomarker tests · Biomarker Testing for Cancer Treatment

Targeted therapies used to treat AML include:

gemtuzumab ozogamicin

Sources: gemtuzumab ozogamicin

midostaurin

Sources: midostaurin

quizartinib

Sources: quizartinib

revumenib

Sources: revumenib

Less-intensive targeted therapies in people who are unable or unwilling to receive other treatments include:

enasidenib

Sources: enasidenib

gilteritinib

Sources: gilteritinib

glasdegib

Sources: glasdegib

ivosidenib

Sources: ivosidenib

venetoclax

Sources: venetoclax

Learn more about Targeted Therapy to Treat Cancer.

Sources: Targeted Therapy to Treat Cancer

For patients · Treatment Option Overview / The following types of treatment are used:

Other drug therapy

Source: Acute Myeloid Leukemia Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: May 16, 2025. Captured 2026-09-09.

Arsenic trioxide and all-trans retinoic acid (ATRA) are anticancer drugs that kill leukemia cells, stop the leukemia cells from dividing, or help the leukemia cells mature into white blood cells. These drugs are used in the treatment of a subtype of AML called acute promyelocytic leukemia.

Sources: Arsenic trioxide · all-trans retinoic acid · acute promyelocytic leukemia

For patients · Treatment Option Overview

New types of treatment are being tested in clinical trials.

Source: Acute Myeloid Leukemia Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: May 16, 2025. Captured 2026-09-09.

For some people, joining a clinical trial may be an option. There are different types of clinical trials for people with cancer. For example, a treatment trial tests new treatments or new ways of using current treatments. Supportive care and palliative care trials look at ways to improve quality of life, especially for those who have side effects from cancer and its treatment.

You can use the clinical trial search to find NCI-supported cancer clinical trials accepting participants. The search allows you to filter trials based on the type of cancer, your age, and where the trials are being done. Clinical trials supported by other organizations can be found on the ClinicalTrials.gov website.

Sources: clinical trial search · ClinicalTrials.gov

Learn more about clinical trials, including how to find and join one, at Clinical Trials Information for Patients and Caregivers.

Sources: Clinical Trials Information for Patients and Caregivers

For patients · Treatment Option Overview

Treatment for acute myeloid leukemia may cause side effects.

Source: Acute Myeloid Leukemia Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: May 16, 2025. Captured 2026-09-09.

For information about side effects caused by treatment for cancer, visit our Side Effects page.

Sources: side effects · Side Effects

For patients · Treatment Option Overview

Follow-up care may be needed.

Source: Acute Myeloid Leukemia Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: May 16, 2025. Captured 2026-09-09.

As you go through treatment, you will have follow-up tests or check-ups. Some tests that were done to diagnose or stage the cancer may be repeated to see how well the treatment is working. Decisions about whether to continue, change, or stop treatment may be based on the results of these tests.

Sources: diagnose · stage

Some of the tests will continue to be done from time to time after treatment has ended. The results of these tests can show if your condition has changed or if the cancer has recurred (come back).

For patients

Treatment of Untreated Acute Myeloid Leukemia

Source: Acute Myeloid Leukemia Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: May 16, 2025. Captured 2026-09-09.

Standard treatment of untreated acute myeloid leukemia (AML) during the remission induction phase depends on the subtype of AML and may include:

Sources: Standard treatment · remission induction · subtype

combination chemotherapy that includes cytarabine

Sources: combination chemotherapy · cytarabine

combination chemotherapy with targeted therapy (midostaurin or quizartinib), for people whose AML has a mutation in the FLT3 gene

Sources: targeted therapy · midostaurin · quizartinib · mutation · FLT3 gene

combination chemotherapy with the targeted therapy drug gemtuzumab ozogamicin

Sources: gemtuzumab ozogamicin

intrathecal chemotherapy (cytarabine or methotrexate), for central nervous system (CNS) leukemia

Sources: intrathecal chemotherapy · methotrexate · central nervous system

supportive care

Sources: supportive care

For older adults or people who are unable or unwilling to receive intensive chemotherapy, the following may be continued as long as the person benefits or until toxic effects occur:

Sources: intensive chemotherapy · toxic

targeted therapy (enasidenib, gilteritinib, glasdegib, ivosidenib, or venetoclax)

Sources: enasidenib · gilteritinib · glasdegib · ivosidenib · venetoclax)

low-dose chemotherapy (azacitidine, low-dose cytarabine, or decitabine)

Sources: low-dose chemotherapy · azacitidine · cytarabine · decitabine

targeted therapy with low-dose chemotherapy

intrathecal chemotherapy, for CNS leukemia

supportive care

Learn more about these treatments in the Treatment Option Overview.

Sources: Treatment Option Overview

Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.

Sources: clinical trial search · General information

For patients

Treatment of Acute Myeloid Leukemia in Remission

Source: Acute Myeloid Leukemia Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: May 16, 2025. Captured 2026-09-09.

Treatment of acute myeloid leukemia (AML) during the remission phase depends on the subtype of AML and may include:

Sources: remission · subtype

combination chemotherapy that includes cytarabine

Sources: combination chemotherapy · cytarabine

maintenance therapy with midostaurin, for people whose AML has a mutation in the FLT3 gene

Sources: maintenance therapy · midostaurin · mutation · FLT3 gene

maintenance therapy with chemotherapy

Sources: chemotherapy

high-dose chemotherapy and stem cell transplant using the patient's stem cells

Sources: high-dose chemotherapy · stem cell transplant · stem cells

high-dose chemotherapy, with or without radiation therapy, or reduced-intensity therapy, followed by a stem cell transplant using donor stem cells

Sources: donor

Learn more about these treatments in Treatment Option Overview.

Sources: Treatment Option Overview

Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.

Sources: clinical trial search · General information

For patients

Treatment of Refractory or Recurrent Acute Myeloid Leukemia

Source: Acute Myeloid Leukemia Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: May 16, 2025. Captured 2026-09-09.

There is no standard treatment for refractory or recurrent acute myeloid leukemia (AML). Treatment depends on the subtype of AML and may include:

Sources: standard treatment · refractory · recurrent · subtype

combination chemotherapy

Sources: combination chemotherapy

targeted therapy with enasidenib, gemtuzumab ozogamicin, gilteritinib, ivosidenib, or revumenib

Sources: targeted therapy · enasidenib · gemtuzumab ozogamicin · gilteritinib · ivosidenib · revumenib

stem cell transplant using donor stem cells

Sources: stem cell transplant · donor · stem cells

Learn more about these treatments in the Treatment Option Overview.

Sources: Treatment Option Overview

Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.

Sources: clinical trial search · General information

For patients

Treatment of Acute Promyelocytic Leukemia

Source: Acute Myeloid Leukemia Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: May 16, 2025. Captured 2026-09-09.

Treatment of newly diagnosed acute promyelocytic leukemia (APL) may include:

Sources: acute promyelocytic leukemia

all-trans retinoic acid (ATRA) plus arsenic trioxide (ATO), for low-risk to intermediate-risk disease

Sources: all-trans retinoic acid · arsenic trioxide · low-risk

ATRA plus combination chemotherapy, followed by ATO, for high-risk disease

Sources: combination chemotherapy · high-risk

Learn more about these treatments in the Treatment Option Overview.

Sources: Treatment Option Overview

Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.

Sources: clinical trial search · General information

For patients

Treatment of Recurrent Acute Promyelocytic Leukemia

Source: Acute Myeloid Leukemia Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: May 16, 2025. Captured 2026-09-09.

Treatment of recurrent acute promyelocytic leukemia (APL) may include:

Sources: recurrent · acute promyelocytic leukemia

arsenic trioxide (ATO) with or without chemotherapy

Sources: arsenic trioxide · chemotherapy

stem cell transplant using the patient's stem cells or donor stem cells

Sources: stem cell transplant · stem cells · donor

Learn more about these treatments in the Treatment Option Overview.

Sources: Treatment Option Overview

Studies

S0106 Cytarabine and Daunorubicin w/ or w/o Gemtuzumab Followed By HD Cytarabine and Either Gemtuzumab or Nothing in de Novo AML

NCT00085709 · COMPLETED · phase3

Leukemia

ClinicalTrials.gov record

Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia

NCT00091234 · UNKNOWN · phase2, phase3

Leukemia

ClinicalTrials.gov record

AIDA2000 - Risk-Adapted Therapy for Patients With Acute Promyelocytic Leukemia

NCT00180128 · UNKNOWN · phase4

Leukemia, Promyelocytic, Acute

ClinicalTrials.gov record

Safety and Effectiveness of Granulocyte Transfusions in Resolving Infection in People With Neutropenia (The RING Study)

NCT00627393 · COMPLETED · phase3

Neutropenia, Infection

ClinicalTrials.gov record

Daunorubicin, Cytarabine, and Midostaurin in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

NCT00651261 · UNKNOWN · phase3

Leukemia

ClinicalTrials.gov record

Efficacy and Safety of RAD001 in Patients Aged 18 and Over With Angiomyolipoma Associated With Either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM)

NCT00790400 · COMPLETED · phase3

Tuberous Sclerosis Complex (TSC), Lymphangioleiomyomatosis (LAM)

ClinicalTrials.gov record

Clinical Phase III Trial Treosulfan-based Conditioning Versus Reduced-intensity Conditioning (RIC)

NCT00822393 · COMPLETED · phase3

Acute Myeloid Leukemia, Myelodysplastic Syndrome

ClinicalTrials.gov record

Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML)

NCT01074047 · COMPLETED · phase3

Acute Myeloid Leukemia

ClinicalTrials.gov record

A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome

NCT01546038 · COMPLETED · phase2

Acute Myeloid Leukemia

ClinicalTrials.gov record

Phase III Study of CPX-351 Versus 7+3 in Patients 60-75 Years Old With Untreated High Risk (Secondary) Acute Myeloid Leukemia

NCT01696084 · COMPLETED · phase3

High Risk Acute Myeloid Leukemia

ClinicalTrials.gov record

Efficacy of Oral Azacitidine Plus Best Supportive Care as Maintenance Therapy in Subjects With Acute Myeloid Leukemia (AML) in Complete Remission

NCT01757535 · COMPLETED · phase3

Leukemia, Myeloid, Acute

ClinicalTrials.gov record

Standard of Care +/- Midostaurin to Prevent Relapse Post Stem Cell Transplant in Patients With FLT3-ITD Mutated AML

NCT01883362 · COMPLETED · phase2

Acute Myeloid Leukemia

ClinicalTrials.gov record

Phase 1/2 Study of Enasidenib (AG-221) in Adults With Advanced Hematologic Malignancies With an Isocitrate Dehydrogenase Isoform 2 (IDH2) Mutation

NCT01915498 · COMPLETED · phase1, phase2

Hematologic Neoplasms

ClinicalTrials.gov record

Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation

NCT02074839 · RECRUITING · phase1

Relapsed or Refractory Acute Myeloid Leukemia (AML), Untreated AML, Other IDH1-mutated Positive Hematologic Malignancies, Myelodysplastic Syndromes

ClinicalTrials.gov record

Tagraxofusp in Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm or Acute Myeloid Leukemia

NCT02113982 · COMPLETED · phase1, phase2

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), Acute Myeloid Leukemia (AML)

ClinicalTrials.gov record

Study of ABT-199 (GDC-0199) in Combination With Azacitidine or Decitabine (Chemo Combo) in Subjects With Acute Myelogenous Leukemia (AML)

NCT02203773 · TERMINATED · phase1

Acute Myelogenous Leukemia, Myelogenous Leukemia, Treatment Naive AML

ClinicalTrials.gov record

A Study Evaluating Venetoclax in Combination With Low-Dose Cytarabine in Treatment-Naïve Participants With Acute Myelogenous Leukemia

NCT02287233 · COMPLETED · phase1, phase2

Acute Myelogenous Leukemia, AML

ClinicalTrials.gov record

Quizartinib With Standard of Care Chemotherapy and as Continuation Therapy in Patients With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia (AML)

NCT02668653 · COMPLETED · phase3

Acute Myeloid Leukemia, Leukemia

ClinicalTrials.gov record

Open-label Study of FT-2102 With or Without Azacitidine or Cytarabine in Patients With AML or MDS With an IDH1 Mutation

NCT02719574 · COMPLETED · phase1, phase2

Acute Myeloid Leukemia, Acute Myelogenous Leukemia, Myelodysplastic Syndrome

ClinicalTrials.gov record

A Study of Venetoclax in Combination With Azacitidine Versus Azacitidine in Treatment Naïve Participants With Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Therapy

NCT02993523 · ACTIVE NOT RECRUITING · phase3

Acute Myeloid Leukemia (AML)

ClinicalTrials.gov record

A Study of Venetoclax in Combination With Low Dose Cytarabine Versus Low Dose Cytarabine Alone in Treatment Naive Patients With Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy

NCT03069352 · COMPLETED · phase3

Acute Myeloid Leukemia (AML)

ClinicalTrials.gov record

Study of AG-120 (Ivosidenib) vs. Placebo in Combination With Azacitidine in Participants With Previously Untreated Acute Myeloid Leukemia With an IDH1 Mutation

NCT03173248 · ACTIVE NOT RECRUITING · phase3

Newly Diagnosed Acute Myeloid Leukemia (AML), Untreated AML, AML Arising From Myelodysplastic Syndrome (MDS), Leukemia, Myeloid, Acute

ClinicalTrials.gov record

Study of ASTX727 vs IV Decitabine in Participants With MDS, CMML, and AML

NCT03306264 · COMPLETED · phase3

Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, Acute Myeloid Leukemia

ClinicalTrials.gov record

Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCN

NCT03386513 · ACTIVE NOT RECRUITING · phase1, phase2

Blastic Plasmacytoid Dendritic Cell Neoplasm, Myeloproliferative Neoplasm

ClinicalTrials.gov record

Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia

NCT03836209 · COMPLETED · phase2

Acute Myeloid Leukemia

ClinicalTrials.gov record

A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation

NCT04065399 · RECRUITING · phase1, phase2

Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Mixed Lineage Acute Leukemia, Mixed Phenotype Acute Leukemia, Acute Leukemia of Ambiguous Lineage

ClinicalTrials.gov record

First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia

NCT04067336 · ACTIVE NOT RECRUITING · phase1, phase2

Advanced Malignant Neoplasm, Acute Myeloid Leukemia, Mixed Lineage Leukemia, Mixed Lineage Acute Leukemia, Acute Leukemia of Ambiguous Lineage, Mixed Phenotype Acute Leukemia,...

ClinicalTrials.gov record

Pharmacokinetics, Safety, and Efficacy of ASTX727 in Combination With Venetoclax in Acute Myeloid Leukemia (AML)

NCT04657081 · ACTIVE NOT RECRUITING · phase1, phase2

Acute Myeloid Leukemia

ClinicalTrials.gov record

Precision-T: A Randomized Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies

NCT05316701 · ACTIVE NOT RECRUITING · phase3

Acute Myeloid Leukemia, Acute Lymphoid Leukemia, Mixed Phenotype Acute Leukemia, Undifferentiated Leukemia, Myelodysplastic Syndrome, Acute Leukemia, Therapy-Related...

ClinicalTrials.gov record

Study of Three Different Schedules of Low-Dose Decitabine in Myelodysplastic Syndrome (MDS)

NCT00067808 · COMPLETED · phase2

Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia

ClinicalTrials.gov record

Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers

NCT00074490 · TERMINATED · phase2

Lymphoma, Leukemia, Myeloproliferative Disorders, Multiple Myleoma, Myelodysplastic Syndrome

ClinicalTrials.gov record

Idarubicin, Cytarabine, and Tipifarnib in Treating Patients With Newly Diagnosed Myelodysplastic Syndromes or Acute Myeloid Leukemia

NCT00096122 · COMPLETED · phase1, phase2

Adult Acute Basophilic Leukemia, Adult Acute Eosinophilic Leukemia, Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0),...

ClinicalTrials.gov record

Low-Dose Decitabine in Myelodysplastic Syndrome Post Azacytidine Failure

NCT00113321 · TERMINATED · phase2

Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia

ClinicalTrials.gov record

Aprepitant in Preventing Nausea and Vomiting in Patients Who Are Undergoing a Stem Cell Transplant

NCT00248547 · COMPLETED · na

Cancer

ClinicalTrials.gov record

Study of Immune Response Modifier in the Treatment of Hematologic Malignancies

NCT00276159 · TERMINATED · phase2

Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Non-Hodgkin's Lymphoma, Hodgkin's Lymphoma, Multiple Myeloma, Chronic Lymphocytic Leukemia

ClinicalTrials.gov record

Oral Clofarabine Study in Patients With Myelodysplastic Syndrome

NCT00299156 · COMPLETED · phase2

Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia

ClinicalTrials.gov record

Myeloablative Umbilical Cord Blood Transplantation in Hematological Diseases

NCT00309842 · COMPLETED · phase2

Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, Chronic Myelogenous Leukemia, Myelofibrosis, MDS, Refractory Anemia, Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia,...

ClinicalTrials.gov record

Azacitidine With or Without Entinostat in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia

NCT00313586 · COMPLETED · phase2

Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22);...

ClinicalTrials.gov record

T Cell Depletion for Recipients of HLA Haploidentical Related Donor Stem Cell Grafts

NCT00368355 · COMPLETED · phase2

Acute Lymphoblastic Leukemia, Non Hodgkins Lymphoma, Myelodysplastic Syndrome, Acute Myeloid Leukemia, Chronic Myelogenous Leukemia, Hemophagocytic Lymphohistiocytosis (HLH),...

ClinicalTrials.gov record

Sunitinib in Treating Patients With Idiopathic Myelofibrosis

NCT00387426 · TERMINATED · phase2

Accelerated Phase Chronic Myelogenous Leukemia, Acute Undifferentiated Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission,...

ClinicalTrials.gov record

MS-275 and GM-CSF in Treating Patients With Myelodysplastic Syndrome and/or Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphocytic Leukemia

NCT00462605 · COMPLETED · phase2

Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic...

ClinicalTrials.gov record

Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation and Donor Bone Marrow Transplant in Treating Patients With Advanced Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or High-Risk Myelodysplastic Syndrome

NCT00589316 · TERMINATED · phase1

Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, CD45-Positive...

ClinicalTrials.gov record

Antithymocyte Globulin, Clofarabine, and Rituximab in Treating Patients After an Unsuccessful Stem Cell Transplant

NCT00617929 · TERMINATED · phase2

Cancer

ClinicalTrials.gov record

Reduced Intensity Total Body Irradiation + Thymoglobulin Followed by Allogeneic PBSCT

NCT00709592 · COMPLETED · phase2

Non-Hodgkin's Lymphoma, Leukemia, Multiple Myeloma, Acute Myeloid Leukemia, Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia, Myelodysplastic Syndrome

ClinicalTrials.gov record

Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer

NCT00723099 · COMPLETED · phase2

Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Aggressive Non-Hodgkin Lymphoma, Chronic Myelogenous Leukemia, Chronic Phase Chronic Myelogenous Leukemia, Indolent...

ClinicalTrials.gov record

Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia

NCT00843882 · ACTIVE NOT RECRUITING · phase3

Anemia, Chronic Myelomonocytic Leukemia, De Novo Myelodysplastic Syndrome, Myelodysplastic Syndrome

ClinicalTrials.gov record

A Phase Ib/IIb, Open-label, Multi-center, Study of Oral Panobinostat Administered With 5-Azacitidine (in Adult Patients With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML).

NCT00946647 · COMPLETED · phase1, phase2

Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, Acute Myeloid Leukemia

ClinicalTrials.gov record

Mismatched Transplantation Using High-dose Post-transplant Cyclophosphamide

NCT01010217 · COMPLETED · phase2

Blood Stem Cell Transplant Failure, Leukemia, Hematologic Malignancies

ClinicalTrials.gov record

Pilot of Abatacept-based Immunosuppression for Prevention of Acute GvHD During Unrelated Donor HCT

NCT01012492 · COMPLETED · phase2

AML, ALL, Undifferentiated Leukemia, Biphenotypic Leukemia, Refractory Anemia, Refractory Anemia With Ringed Sideroblasts, Refractory Cytopenia With Multilineage Dysplasia,...

ClinicalTrials.gov record

Clofarabine, Cytarabine, and Filgrastim in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia, Advanced Myelodysplastic Syndrome, and/or Advanced Myeloproliferative Neoplasm

NCT01101880 · COMPLETED · phase2

Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid...

ClinicalTrials.gov record

Prophylactic White Cell Transfusions Versus Therapeutic White Cell Transfusions in Patients With Leukemia

NCT01204788 · TERMINATED · phase2

Leukemia

ClinicalTrials.gov record

Sorafenib and 5-Azacitidine in Acute Leukemia + Myelodysplastic Syndrome

NCT01254890 · COMPLETED · phase1, phase2

Leukemia

ClinicalTrials.gov record

Yttrium-90 Anti-CD45 Monoclonal Antibody BC8 Followed by Donor Stem Cell Transplant in Treating Patients With High-Risk AML, ALL, or MDS

NCT01300572 · COMPLETED · phase1

Chronic Myelomonocytic Leukemia, Previously Treated Myelodysplastic Syndrome, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Refractory...

ClinicalTrials.gov record

Preservation of Ovarian Function After Hematopoietic Cell Transplant

NCT01343368 · TERMINATED · phase2

Multiple Myeloma, Non-Hodgkin Lymphoma, Hodgkin Disease, Acute Myeloid Leukemia, Myeloproliferative Disorders

ClinicalTrials.gov record

Phase I Study of OPB-51602 in Patients With Hematologic Malignancies

NCT01344876 · COMPLETED · phase1

Multiple Myeloma, Non-Hodgkin Lymphoma, Acute Myeloid Leukemia, Acute Lymphoid Leukemia, Chronic Myeloid Leukemia

ClinicalTrials.gov record

A Study of 5-Azacitidine (Vidaza®) in Patients With Chronic Myelomonocytic Leukemia

NCT01350947 · COMPLETED · phase2

Chronic Myelomonocytic Leukemia

ClinicalTrials.gov record

Fludarabine Based Conditioning for Allogeneic Transplantation for Advanced Hematologic Malignancies

NCT01499147 · COMPLETED · na

Acute Myeloid Leukemia, Acute Leukemia, Chronic Myelogenous Leukemia, Malignant Lymphoma, Hodgkin's Disease, Multiple Myeloma, Lymphocytic Leukemia, Myeloproliferative...

ClinicalTrials.gov record

Allogeneic Transplantation Using Timed Sequential Busulfan and Fludarabine Conditioning

NCT01572662 · COMPLETED · phase2

Leukemia, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Myeloproliferative Diseases, Non-Hodgkins Lymphoma,...

ClinicalTrials.gov record

Consolidation Therapy for Acute Myeloid Leukemia Guided by Leukemia Stem Cell Behavior

NCT01588951 · TERMINATED · phase2, phase3

Acute Myeloid Leukemia

ClinicalTrials.gov record

Bulk Versus Fractionated Stem Cell Infusions in Patients With Hematologic Malignancies Undergoing Stem Cell Transplantation

NCT01596257 · COMPLETED · phase2

Leukemia

ClinicalTrials.gov record

Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia

NCT01620216 · TERMINATED · phase2

Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid...

ClinicalTrials.gov record

Erlotinib Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

NCT01664897 · COMPLETED · phase2

Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11, Adult Acute Myeloid Leukemia With...

ClinicalTrials.gov record

Phase II Study of Lenalidomide and Eltrombopag in Patients With Symptomatic Anemia

NCT01772420 · COMPLETED · phase2

Adult Myelodysplastic Syndrome, Anemia, Chronic Myelomonocytic Leukemia

ClinicalTrials.gov record

GVAX vs. Placebo for MDS/AML After Allo HSCT

NCT01773395 · TERMINATED · phase2

Myelodysplastic Syndrome, Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia

ClinicalTrials.gov record

A Sequential Two-Stage Dose Escalation Study to Evaluate the Safety and Efficacy of Ruxolitinib

NCT01776723 · COMPLETED · phase1, phase2

Myelomonocytic Leukemia

ClinicalTrials.gov record

Chemotherapy in Treating Patients With Myelodysplastic Syndrome Before Donor Stem Cell Transplant

NCT01812252 · COMPLETED · phase2

Chronic Myelomonocytic Leukemia, de Novo Myelodysplastic Syndrome, Myelodysplastic Syndrome, Secondary Myelodysplastic Syndrome

ClinicalTrials.gov record

Donor Natural Killer Cells and Donor Stem Cell Transplant in Treating Patients With High Risk Myeloid Malignancies

NCT01823198 · COMPLETED · phase1, phase2

Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Erythroid Leukemia, Acute Megakaryoblastic Leukemia, Acute Myeloid Leukemia, Acute Myeloid Leukemia...

ClinicalTrials.gov record

Idarubicin, Cytarabine, and Pravastatin Sodium in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes

NCT01831232 · COMPLETED · na

Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia...

ClinicalTrials.gov record

Phase II Hedgehog Inhibitor for Myelodysplastic Syndrome (MDS)

NCT01842646 · COMPLETED · phase2

Myelodysplastic Syndrome (MDS), Chronic Myelomonocytic Leukemia (CMML)

ClinicalTrials.gov record

Bioelectrical Impedance Measurement for Predicting Treatment Outcome in Patients With Newly Diagnosed Acute Leukemia

NCT01869777 · COMPLETED · na

Acute Undifferentiated Leukemia, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With...

ClinicalTrials.gov record

Treatment for Relapsed/Refractory AML Based on a High Throughput Drug Sensitivity Assay

NCT01872819 · COMPLETED · na

Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia...

ClinicalTrials.gov record

Clofarabine and Melphalan Before Donor Stem Cell Transplant in Treating Patients With Myelodysplasia, Acute Leukemia in Remission, or Chronic Myelomonocytic Leukemia

NCT01885689 · ACTIVE NOT RECRUITING · phase2

Adult Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Adult Acute Myeloid Leukemia in Remission,...

ClinicalTrials.gov record

Quizartinib With Azacitidine or Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

NCT01892371 · COMPLETED · phase1, phase2

FLT3 Gene Mutation Negative, FLT3 Internal Tandem Duplication Positive, Recurrent Acute Myeloid Leukemia, Recurrent Chronic Myelomonocytic Leukemia, Recurrent Myelodysplastic...

ClinicalTrials.gov record

Study of Vosaroxin and Decitabine in Older Patients With Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome

NCT01893320 · COMPLETED · phase1, phase2

Leukemia

ClinicalTrials.gov record

Treo/Flu/TBI With Donor Stem Cell Transplant for Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia

NCT01894477 · UNKNOWN · phase2

Acute Myeloid Leukemia in Remission, Chronic Myelomonocytic Leukemia, Minimal Residual Disease, Myelodysplastic Syndrome, Myelodysplastic/Myeloproliferative Neoplasm,...

ClinicalTrials.gov record

A Dose Escalation Study to Investigate the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD) and Clinical Activity of GSK525762 in Subjects With Relapsed, Refractory Hematologic Malignancies

NCT01943851 · COMPLETED · phase2

Neoplasms

ClinicalTrials.gov record

Tac, Mini-MTX, MMF Versus Tac, MTX for GVHD Prevention

NCT01951885 · COMPLETED · phase3

Chronic Myelogenous Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Acute Biphenotypic Leukemia, Myelodysplastic Syndrome, Myeloproliferative Neoplasm,...

ClinicalTrials.gov record

Eltrombopag With Decitabine in Advanced Myelodysplastic Syndrome (MDS)

NCT02010645 · TERMINATED · phase2

Leukemia

ClinicalTrials.gov record

Clofarabine, Idarubicin, Cytarabine, Vincristine Sulfate, and Dexamethasone in Treating Patients With Newly Diagnosed or Relapsed Mixed Phenotype Acute Leukemia

NCT02135874 · COMPLETED · phase2

Acute Bilineal Leukemia, Acute Biphenotypic Leukemia, Acute Leukemia of Ambiguous Lineage, Acute Undifferentiated Leukemia, Mixed Phenotype Acute Leukemia, Mixed Phenotype...

ClinicalTrials.gov record

Study of FF-10501-01 in Patients With Relapsed or Refractory Hematological Malignancies

NCT02193958 · COMPLETED · phase1, phase2

AML, CMML, MDS

ClinicalTrials.gov record

Repeat Transplantation for Relapsed or Refractory Hematologic Malignancies Following Prior Transplantation

NCT02259348 · TERMINATED · phase2

Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Myeloid Sarcoma, Chronic Myelogenous Leukemia (CML), Juvenile Myelomonocytic Leukemia (JMML), Myelodysplastic...

ClinicalTrials.gov record

Tagraxofusp (SL-401) in Participants With Chronic Myelomonocytic Leukemia (CMML) and Myelofibrosis (MF)

NCT02268253 · COMPLETED · phase1, phase2

Myelofibrosis, Chronic Myelomonocytic Leukemia

ClinicalTrials.gov record

A Combination Study of PF-04449913 (Glasdegib) and Azacitidine In Untreated MDS, AML and CMML Patients

NCT02367456 · COMPLETED · phase1

Myelodysplastic Syndrome, Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia

ClinicalTrials.gov record

Nivolumab and Azacitidine With or Without Ipilimumab in Treating Patients With Refractory/Relapsed or Newly Diagnosed Acute Myeloid Leukemia

NCT02397720 · COMPLETED · phase2

Acute Bilineal Leukemia, Acute Biphenotypic Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, Myelodysplastic...

ClinicalTrials.gov record

A Study of E6201 for the Treatment of Advanced Hematologic Malignancies With FLT3 and/or Ras Mutations

NCT02418000 · TERMINATED · phase1, phase2

AML, MDS, CMML

ClinicalTrials.gov record

Phase I/II, Study of Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) + Sorafenib in Acute Myeloid Leukemia

NCT02530476 · COMPLETED · phase1, phase2

Leukemia, Acute Myeloid Leukemia

ClinicalTrials.gov record

WEE1 Inhibitor AZD1775 With or Without Cytarabine in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome

NCT02666950 · COMPLETED · phase2

Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome With Isolated Del(5q), Myelodysplastic/Myeloproliferative Neoplasm, Previously Treated Myelodysplastic Syndrome,...

ClinicalTrials.gov record

AMG 176 First in Human Trial in Participants With Relapsed or Refractory Multiple Myeloma and Participants With Relapsed or Refractory Acute Myeloid Leukemia

NCT02675452 · TERMINATED · phase1

Relapsed or Refractory Multiple Myeloma, Relapsed or Refractory Acute Myeloid Leukemia

ClinicalTrials.gov record

Guadecitabine and Donor Lymphocyte Infusion in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Relapsing After Allogeneic Stem Cell Transplant

NCT02684162 · COMPLETED · phase2

Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Recurrent Myelodysplastic Syndrome

ClinicalTrials.gov record

UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep

NCT02722668 · COMPLETED · phase2

Acute Leukemia, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia/Lymphoma, Burkitt's Lymphoma, Natural Killer Cell Malignancies, Chronic Myelogenous Leukemia,...

ClinicalTrials.gov record

Electrophysiological Biomarkers of Chemotherapy-related Cognitive Impairment and Recovery

NCT02767388 · COMPLETED · Phase not reported

Myelodysplastic Syndrome, Effects of Chemotherapy, Mild Cognitive Impairment, Multiple Myeloma, Non-hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Acute Lymphoid Leukemia,...

ClinicalTrials.gov record

Tipifarnib in Subjects With Chronic Myelomonocytic Leukemia, Other MDS/MPN, and Acute Myeloid Leukemia

NCT02807272 · COMPLETED · phase2

Leukemia, Myelomonocytic, Chronic

ClinicalTrials.gov record

Leukemia Stem Cell Detection in Acute Myeloid Leukemia

NCT02927938 · TERMINATED · phase3

Acute Myeloid Leukemia (AML)

ClinicalTrials.gov record

Glutaminase Inhibitor CB-839 and Azacitidine in Treating Patients With Advanced Myelodysplastic Syndrome

NCT03047993 · COMPLETED · phase1, phase2

Acute Myeloid Leukemia With Multilineage Dysplasia, Blasts 20-30 Percent of Bone Marrow Nucleated Cells, Blasts 20-30 Percent of Peripheral Blood White Cells, Chronic...

ClinicalTrials.gov record

Phase 1b/2 Safety and Efficacy of APR-246 w/Azacitidine for tx of TP53 Mutant Myeloid Neoplasms

NCT03072043 · COMPLETED · phase1, phase2

Myelodysplastic Syndrome, Acute Myeloid Leukemia, Myeloproliferative Neoplasm, Chronic Myelomonocytic Leukemia

ClinicalTrials.gov record

Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphoma

NCT03096782 · COMPLETED · phase2

Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Biphenotypic Leukemia, Acute Leukemia, Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia in...

ClinicalTrials.gov record

Recombinant EphB4-HSA Fusion Protein and Azacitidine or Decitabine for Relapsed or Refractory Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia Patients Previously Treated With a Hypomethylating Agent

NCT03146871 · TERMINATED · phase2

Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, Previously Treated Myelodysplastic Syndrome, Recurrent Acute Myeloid...

ClinicalTrials.gov record

Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia

NCT03289910 · ACTIVE NOT RECRUITING · phase2

Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Atypical Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Essential...

ClinicalTrials.gov record

DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, Decitabine, and Nivolumab in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia

NCT03358719 · COMPLETED · phase1

Acute Myeloid Leukemia, Blasts 30 Percent or Less of Bone Marrow Nucleated Cells, Chronic Myelomonocytic Leukemia, High Risk Myelodysplastic Syndrome, Myelodysplastic Syndrome,...

ClinicalTrials.gov record

Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects With Selected Relapsed or Refractory Hematological Malignancies

NCT03465540 · TERMINATED · phase1

Multiple Myeloma, Acute Myeloid Leukemia, Non-Hodgkins Lymphoma, Myelodysplastic Syndrome, AML, MDS, NHL

ClinicalTrials.gov record

Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression

NCT03480360 · COMPLETED · phase3

Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Myelodysplasia, Myeloproliferative Disorder, Myelofibrosis, Lymphoma, Lymphoma, Non-Hodgkin,...

ClinicalTrials.gov record

Study to Investigate the Safety and Clinical Activity of GSK3326595 and Other Agents to Treat Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)

NCT03614728 · TERMINATED · phase1, phase2

Neoplasms

ClinicalTrials.gov record

Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy

NCT03674411 · ACTIVE NOT RECRUITING · phase2

Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, Biphenotypic/Undifferentiated Leukemia, Chronic Myelogenous Leukemia, Myelodysplasia, Relapsed Large Cell Lymphoma, Mantle...

ClinicalTrials.gov record

Ruxolitinib for the Treatment of Chronic Myelomonocytic Leukemia (CMML): A Phase 2 Expansion

NCT03722407 · ACTIVE NOT RECRUITING · phase2

Chronic Myelomonocytic Leukemia, Leukemia

ClinicalTrials.gov record

Total Body Irradiation +/- Total Lymphoid Irradiation & Anti-Thymocyte Globulin in Non-myeloablative Hematopoietic Cell Transplantation

NCT03734601 · COMPLETED · phase2

Acute Myeloid Leukemia, Myelodysplastic Syndromes, Myeloproliferative Disorder, Chronic Lymphocytic Leukemia, B-cell Lymphoma, T-cell Lymphoma, Non Hodgkin Lymphoma, Hodgkin...

ClinicalTrials.gov record

TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies

NCT03849651 · ACTIVE NOT RECRUITING · phase2

Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS), NK-Cell Leukemia, Hodgkin Lymphoma, Non Hodgkin Lymphoma (NHL), Juvenile...

ClinicalTrials.gov record

A Phase 1 Trial of CD25/Treg-depleted DLI Plus Ipilimumab for Myeloid Disease Relapse After Matched-HCT

NCT03912064 · ACTIVE NOT RECRUITING · phase1

Acute Myeloid Leukemia, Myelodysplastic Syndromes, Myeloproliferative Neoplasms, Chronic Myelomonocytic Leukemia, Myelofibrosis

ClinicalTrials.gov record

Study of NMS-03592088 in Patients With Relapsed or Refractory AML or CMML

NCT03922100 · TERMINATED · phase1, phase2

Acute Myeloid Leukemia (AML), Chronic Myelomonocytic Leukemia (CMML)

ClinicalTrials.gov record

Study of CAR T-cell Therapy in Acute Myeloid Leukemia and Multiple Myeloma

NCT04097301 · TERMINATED · phase1, phase2

Acute Myeloid Leukemia, Multiple Myeloma

ClinicalTrials.gov record

Salsalate, Venetoclax, and Decitabine or Azacitidine for the Treatment of Acute Myeloid Leukemia or Advanced Myelodysplasia/Myeloproliferative Disease

NCT04146038 · COMPLETED · phase2

Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myeloblasts 10 Percent or More of Bone Marrow Nucleated Cells, Myelodysplastic Syndrome, Myeloproliferative Neoplasm,...

ClinicalTrials.gov record

Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic Malignancies

NCT04191187 · COMPLETED · phase2

Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Biphenotypic Acute Leukemia, Undifferentiated Leukemia, Prolymphocytic Leukemia, Myelodysplastic Syndromes, Chronic...

ClinicalTrials.gov record

Cobimetinib in Newly Diagnosed or HMA-treated CMML Patients With RAS Pathway Mutations

NCT04409639 · ACTIVE NOT RECRUITING · phase2

Chronic Myelomonocytic Leukemia (CMML)

ClinicalTrials.gov record

Azacitidine, Venetoclax, and Trametinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndrome

NCT04487106 · COMPLETED · phase2

Recurrent Acute Myeloid Leukemia, Recurrent Chronic Myelomonocytic Leukemia, Recurrent Myelodysplastic Syndrome, Refractory Acute Myeloid Leukemia, Refractory Chronic...

ClinicalTrials.gov record

DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia

NCT04752163 · TERMINATED · phase1, phase2

Hematopoietic and Lymphoid Cell Neoplasm, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia, Recurrent Chronic Myelomonocytic Leukemia, Recurrent...

ClinicalTrials.gov record

Comparing the Addition of an Anti-Cancer Drug, Pomalidomide, to the Usual Chemotherapy Treatment (Daunorubicin and Cytarabine Liposome) in Newly Diagnosed Acute Myeloid Leukemia With Myelodysplastic Syndrome-Related Changes

NCT04802161 · ACTIVE NOT RECRUITING · phase2

Acute Myeloid Leukemia, Acute Myeloid Leukemia Post Cytotoxic Therapy, Acute Myeloid Leukemia With Multilineage Dysplasia, Chronic Myelomonocytic Leukemia, Myelodysplastic...

ClinicalTrials.gov record

Continuation Study of B1371019(NCT03416179) and B1371012(NCT02367456) Evaluating Azacitidine With Or Without Glasdegib In Patients With Previously Untreated AML, MDS or CMML

NCT04842604 · COMPLETED · phase3

Acute Myeloid Leukemia, Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia

ClinicalTrials.gov record

A Study of E7820 in People With Bone Marrow (Myeloid) Cancers

NCT05024994 · COMPLETED · phase2

Acute Myeloid Leukemia, Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia

ClinicalTrials.gov record

A Study to Evaluate MK-0482 for Relapsed/Refractory Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic Leukemia (CMML) (MK-0482-002)

NCT05038800 · TERMINATED · phase1

Relapsed or Refractory Acute Myeloid Leukemia, Relapsed or Refractory Chronic Myelomonocytic Leukemia

ClinicalTrials.gov record

Removing Transfusion Dependence as a Barrier to Hospice Enrollment

NCT05063591 · COMPLETED · na

Hematologic Malignancy, Myelodysplastic Syndromes, Acute Myeloid Leukemia, Lymphoma, Leukemia, Myeloma

ClinicalTrials.gov record

Metabolically Optimized, Non-cytotoxic Low Dose Weekly Decitabine/Venetoclax in MDS and AML

NCT05184842 · RECRUITING · phase2

Myelodysplastic Syndromes, Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia

ClinicalTrials.gov record

AMG 176 With Azacitidine in Subjects With Myelodysplastic Syndrome /Chronic Myelomonocytic Leukemia

NCT05209152 · TERMINATED · phase1

Higher Risk Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia

ClinicalTrials.gov record

Enasidenib in MDS &Non-proliferative Chronic Myelomonocytic Leukemia w/o IDH2 Mutation

NCT05282459 · COMPLETED · phase1, phase2

Leukemia, Leukemia, Myeloid, Monocytic Leukemia

ClinicalTrials.gov record

T-cell Receptor α/β Depleted Donor Lymphocyte Infusion

NCT05350163 · TERMINATED · phase1

Lymphoid Leukemia, Acute, Myeloid Malignancy, Plasma Cell Tumor

ClinicalTrials.gov record

Study of CPX-351 (VYXEOS) in Individuals < 22 Years With Secondary Myeloid Neoplasms

NCT05656248 · ACTIVE NOT RECRUITING · phase2

Myeloid Neoplasm

ClinicalTrials.gov record

A Safety, Tolerability and Efficacy Study of NC525 in Subjects With Advanced Myeloid Neoplasms

NCT05787496 · TERMINATED · phase1

Relapsed or Refractory Acute Myeloid Leukemia, Relapsed or Refractory Chronic Myelomonocytic Leukemia, Relapsed or Refractory Myelodysplastic Syndrome

ClinicalTrials.gov record

Disease and treatment settings

Acute Biphenotypic Leukemia

Disease and treatment setting

Acute Biphenotypic Leukemia

Acute Leukemia of Ambiguous Lineage

Disease and treatment setting

Acute Leukemia of Ambiguous Lineage

Acute Myeloid Leukemia

Disease and treatment setting

Acute Myeloid Leukemia

Acute Myeloid Leukemia

Disease and treatment setting

Treatment of Newly Diagnosed AML

Acute Myeloid Leukemia

Disease and treatment setting

Treatment of Untreated Acute Myeloid Leukemia

Acute Myeloid Leukemia with inv(3)(q21.3;q26.2); GATA2, MECOM

Disease and treatment setting

Acute Myeloid Leukemia with inv(3)(q21.3;q26.2); GATA2, MECOM

Acute Undifferentiated Leukemia

Disease and treatment setting

Acute Undifferentiated Leukemia

Blastic Plasmacytoid Dendritic Cell Neoplasm

Disease and treatment setting

Blastic Plasmacytoid Dendritic Cell Neoplasm

Idhifa: refractory Acute Myeloid Leukemia with IDH2 stated without a specific alteration

Disease and treatment setting

1 INDICATIONS AND USAGE IDHIFA is an isocitrate dehydrogenase-2 inhibitor indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation as...

Komzifti: refractory Acute Myeloid Leukemia

Disease and treatment setting

KOMZIFTI is a menin inhibitor indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible nucleophosmin 1 ( NPM1 ) mutation who have no satisfactory alternative treatment...

Lymphoid Leukemia

Disease and treatment setting

Lymphoid Leukemia

Mast Cell Leukemia

Disease and treatment setting

Mast Cell Leukemia

Mixed Phenotype Acute Leukemia

Disease and treatment setting

Mixed Phenotype Acute Leukemia

Mylotarg: refractory Acute Myeloid Leukemia

Disease and treatment setting

1.2 Relapsed or Refractory CD33-positive AML MYLOTARG is indicated for the treatment of relapsed or refractory CD33-positive acute myeloid leukemia in adults and pediatric patients 2 years and older.

ONUREG: Acute Myeloid Leukemia after prior therapy

Disease and treatment setting

ONUREG is a nucleoside metabolic inhibitor indicated for continued treatment of adult patients with acute myeloid leukemia who achieved first complete remission (CR) or complete remission with incomplete blood count recovery (CRi)...

Prolymphocytic Leukemia

Disease and treatment setting

Prolymphocytic Leukemia

recurrent Acute Myeloid Leukemia

Disease and treatment setting

Treatment of Refractory or Recurrent AML

Revuforj: refractory Acute Myeloid Leukemia

Disease and treatment setting

REVUFORJ is indicated for the treatment of relapsed or refractory acute myeloid leukemia with a susceptible nucleophosmin 1 ( NPM1 ) mutation [see Dosage and Administration (2.1) , Clinical Pharmacology (12.1) , and Clinical Studies...

REZLIDHIA: refractory Acute Myeloid Leukemia with IDH1 stated without a specific alteration

Disease and treatment setting

1 INDICATIONS AND USAGE Relapsed or Refractory Acute Myeloid Leukemia REZLIDHIA is indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1...

REZLIDHIA: refractory Acute Myeloid Leukemia with IDH1 stated without a specific alteration, IDH1 mutation

Disease and treatment setting

REZLIDHIA is an isocitrate dehydrogenase-1 (IDH1) inhibitor indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible IDH1 mutation as detected by an FDA-approved test.

RYDAPT: Acute Myeloid Leukemia with FLT3 mutation

Disease and treatment setting

1.1 Acute Myeloid Leukemia RYDAPT is indicated in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation chemotherapy, for the treatment of adult patients with newly diagnosed acute myeloid leukemia...

T-Cell Large Granular Lymphocyte Leukemia

Disease and treatment setting

T-Cell Large Granular Lymphocyte Leukemia

TIBSOVO: Acute Myeloid Leukemia with IDH1 stated without a specific alteration

Disease and treatment setting

1.1 Newly Diagnosed Acute Myeloid Leukemia TIBSOVO is indicated in combination with azacitidine or as monotherapy for the treatment of newly diagnosed acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1)...

TIBSOVO: Acute Myeloid Leukemia with IDH1 stated without a specific alteration, IDH1 mutation

Disease and treatment setting

1 INDICATIONS AND USAGE TIBSOVO is an isocitrate dehydrogenase-1 (IDH1) inhibitor indicated for patients with a susceptible IDH1 mutation as detected by an FDA-approved test with: Newly Diagnosed Acute Myeloid Leukemia (AML) In...

TIBSOVO: refractory Acute Myeloid Leukemia with IDH1 stated without a specific alteration

Disease and treatment setting

1.2 Relapsed or Refractory Acute Myeloid Leukemia TIBSOVO is indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as...

VANFLYTA: Acute Myeloid Leukemia with FLT3 stated without a specific alteration (maintenance) after prior therapy

Disease and treatment setting

1 INDICATIONS AND USAGE VANFLYTA is indicated in combination with standard cytarabine and anthracycline induction and cytarabine consolidation, and as maintenance monotherapy following consolidation chemotherapy, for the treatment of...

Xospata: refractory Acute Myeloid Leukemia with FLT3 mutation

Disease and treatment setting

1 INDICATIONS AND USAGE XOSPATA is a kinase inhibitor indicated for the treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation as detected by an FDA-approved test.

Xospata: refractory Acute Myeloid Leukemia with FLT3 stated without a specific alteration

Disease and treatment setting

1.1 Relapsed or Refractory Acute Myeloid Leukemia XOSPATA is indicated for the treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a FMS-like tyrosine kinase 3 (FLT3) mutation as detected by an...

Drug labels

Allopurinol

Label date 2022-12-21

INDICATIONS AND USAGE THIS IS NOT AN INNOCUOUS DRUG. IT IS NOT RECOMMENDED FOR THE TREATMENT OF ASYMPTOMATIC HYPERURICEMIA. Allopurinol reduces serum and urinary uric acid concentrations. Its use should be individualized for each...

DailyMed label

Allopurinol

Label date 2024-05-22

INDICATIONS AND USAGE THIS IS NOT AN INNOCUOUS DRUG. IT IS NOT RECOMMENDED FOR THE TREATMENT OF ASYMPTOMATIC HYPERURICEMIA. Allopurinol reduces serum and urinary uric acid concentrations. Its use should be individualized for each...

DailyMed label

Allopurinol

Label date 2023-02-01

INDICATIONS AND USAGE THIS IS NOT AN INNOCUOUS DRUG. IT IS NOT RECOMMENDED FOR THE TREATMENT OF ASYMPTOMATIC HYPERURICEMIA. Allopurinol reduces serum and urinary uric acid concentrations. Its use should be individualized for each...

DailyMed label

Daurismo

Label date 2025-12-12

DAURISMO is indicated, in combination with low-dose cytarabine, for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adult patients who are ≥75 years old or who have comorbidities that preclude use of intensive induction...

DailyMed label

Elliotts B

Label date 2024-10-16

INDICATIONS AND USAGE Elliotts B Solution is indicated as a diluent for the intrathecal administration of methotrexate sodium and cytarabine for the prevention or treatment of meningeal leukemia or lymphocytic lymphoma.

DailyMed label

FILKRI

Label date 2026-07-10

FILKRI is a leukocyte growth factor indicated to Decrease the incidence of infection‚ as manifested by febrile neutropenia‚ in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a...

DailyMed label

GRAFAPEX

Label date 2025-01-31

GRAFAPEX is an alkylating drug indicated for: Use in combination with fludarabine as a preparative regimen for allogeneic hematopoietic stem cell transplantation (alloHSCT) in adult and pediatric patients 1 year of age and older with...

DailyMed label

Idamycin PFS

Label date 2026-04-15

IDAMYCIN PFS is indicated for the treatment of adult patients with acute myeloid leukemia (AML) as a component of a combination chemotherapy regimen. IDAMYCIN PFS is an anthracycline topoisomerase inhibitor indicated for the treatment...

DailyMed label

Idhifa

Label date 2025-01-16

IDHIFA is an isocitrate dehydrogenase-2 inhibitor indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved...

DailyMed label

INQOVI

Label date 2026-05-25

INQOVI is a combination of decitabine, a nucleoside metabolic inhibitor, and cedazuridine, a cytidine deaminase inhibitor, indicated: For treatment of adult patients with myelodysplastic syndromes (MDS), including previously treated and...

DailyMed label

Komzifti

Label date 2025-12-09

KOMZIFTI is indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible nucleophosmin 1 ( NPM1 ) mutation who have no satisfactory alternative treatment options [see Dosage...

DailyMed label

Leukine

Label date 2024-12-06

LEUKINE is a leukocyte growth factor indicated: To shorten time to neutrophil recovery and to reduce the incidence of severe and life-threatening infections and infections resulting in death following induction chemotherapy in adult...

DailyMed label

Mylotarg

Label date 2025-12-19

MYLOTARG is a CD33-directed antibody and cytotoxic drug conjugate indicated for: • treatment of newly-diagnosed CD33-positive acute myeloid leukemia (AML) in adults and pediatric patients 1 month and older ( 1.1 ). • treatment of...

DailyMed label

NEUPOGEN

Label date 2026-07-23

NEUPOGEN is a leukocyte growth factor indicated to Decrease the incidence of infection, as manifested by febrile neutropenia, in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a...

DailyMed label

Nivestym

Label date 2025-08-12

NIVESTYM is a leukocyte growth factor indicated to • Decrease the incidence of infection‚ as manifested by febrile neutropenia‚ in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a...

DailyMed label

NYPOZI

Label date 2025-05-01

NYPOZI is a leukocyte growth factor indicated to: Decrease the incidence of infection, as manifested by febrile neutropenia, in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a...

DailyMed label

NYPOZI txid

Label date 2026-01-15

NYPOZI is a leukocyte growth factor indicated to: Decrease the incidence of infection, as manifested by febrile neutropenia, in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a...

DailyMed label

ONUREG

Label date 2026-06-12

ONUREG is indicated for continued treatment of adult patients with acute myeloid leukemia who achieved first complete remission (CR) or complete remission with incomplete blood count recovery (CRi) following intensive induction...

DailyMed label

RELEUKO

Label date 2025-04-24

RELEUKO is a leukocyte growth factor indicated to: Decrease the incidence of infection‚ as manifested by febrile neutropenia‚ in patients with nonmyeloid malignancies receiving myelosuppressive anti- cancer drugs associated with a...

DailyMed label

Revuforj

Label date 2026-02-04

REVUFORJ is a menin inhibitor indicated for: the treatment of relapsed or refractory acute leukemia with a lysine methyltransferase 2A gene ( KMT2A ) translocation as determined by an FDA-authorized test in adult and pediatric patients...

DailyMed label

REZLIDHIA

Label date 2025-11-05

Relapsed or Refractory Acute Myeloid Leukemia REZLIDHIA is indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected...

DailyMed label

RYDAPT

Label date 2026-06-08

RYDAPT is a kinase inhibitor indicated for the treatment of adult patients with: Newly diagnosed acute myeloid leukemia (AML) that is FLT3 mutation-positive as detected by an FDA-approved test, in combination with standard cytarabine...

DailyMed label

TIBSOVO

Label date 2025-12-22

TIBSOVO is an isocitrate dehydrogenase-1 (IDH1) inhibitor indicated for patients with a susceptible IDH1 mutation as detected by an FDA-approved test with: Newly Diagnosed Acute Myeloid Leukemia (AML) In combination with azacitidine or...

DailyMed label

VANFLYTA

Label date 2026-04-16

VANFLYTA is indicated in combination with standard cytarabine and anthracycline induction and cytarabine consolidation, and as maintenance monotherapy following consolidation chemotherapy, for the treatment of adult patients with newly...

DailyMed label

VYXEOS

Label date 2026-01-30

VYXEOS is indicated for the treatment of newly diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) in adults and pediatric patients 1 year and older. VYXEOS is a liposomal...

DailyMed label

Xospata

Label date 2022-01-01

XOSPATA is a kinase inhibitor indicated for the treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation as detected by an FDA-approved test. ( 1.1 ) 1.1 Relapsed or Refractory Acute...

DailyMed label

ZARXIO

Label date 2025-08-29

ZARXIO is a leukocyte growth factor indicated to • Decrease the incidence of infection‚ as manifested by febrile neutropenia‚ in patients with nonmyeloid malignancies receiving myelosuppressive anti‑cancer drugs associated with a...

DailyMed label